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Ulcerative colitis (UC) is a heterogeneous inflammatory bowel disease (IBD) associated 
with chronic inflammation of the gastrointestinal tract. Characterized by genetic and 
immunological abnormalities, UC has overly aggressive T-cell responses to commensal 
bacteria eventually leading to disease pathology. UC is distinguished from Crohn’s 
disease, another form of IBD, in that it is driven by a T helper type 2 (Th2) immune 
response. Oxazolone-induced colitis is a mouse model resembling UC presenting with 
inflammation limited to the distal colon and mixed neutrophil/lymphocyte infiltration in 
the superficial layer of the mucosa. The Th2 cytokines interleukin (IL)-4 and IL-13 are 
associated with the onset of oxazolone colitis and both signal through a common IL-4 
receptor-alpha chain (IL-4Rα). Neutralizing these cytokines prevents or ameliorates 
disease significantly, while neutralizing IL-12 exacerbates disease symptoms. As many 
aspects of the mechanisms involving Th2 cytokines in colitis remain undefined, the aim 
of this study was to investigate the role of IL-4 and IL-13 and the receptors through 
which they signal in oxazolone-induced colitis.  
Previous studies have highlighted a role for IL-4 and IL-13 in mediating oxazolone 
colitis. We show that while IL-13-deficient BALB/c mice were protected from disease 
onset, IL-4Rα-deficient BALB/c mice developed exacerbated disease symptoms. 
Removing IL-13 production from IL-4Rα-deficient mice reversed the susceptible 
phenotype to protection. These results demonstrate that IL-13 is a major disease-causing 
factor, able to signal independently of the IL-4Rα chain. It is likely that IL-13 signals via 
the IL-13Rα2 chain, previously believed to be a decoy receptor for IL-13 only, but more 
recently shown to transduce a signal in cells. Furthermore, the exacerbated phenotype in 
IL-4Rα-deficient mice may suggest that IL-4Rα-responsiveness also influences disease. 
To determine the possible role of IL-4Rα-responsive lymphocytes in colitis, we 
investigated mice lacking this receptor specifically on B cells (mb1creIL-4Rα-/lox) or T 
cells (LckcreIL-4Rα-/lox). Interestingly, both cell specific mouse strains were protected 
from disease. Protection correlated with impaired IgE antibody responses in mb1creIL-
4Rα-/lox mice and neutralizing IgE significantly protected BALB/c mice from the onset of 
colitis. Adoptively transferring CD4+ T helper cells into LckcreIL-4Rα-/lox mice reversed 
protection back to a susceptible phenotype with increased IL-13 production. Together, 
these data suggest that IL-4 responsive CD4+ T cells and IgE-producing B cells are 















Together, our study describes cellular mechanisms underlying oxazolone colitis and 
shows an important role for IL-4Rα signalling in the induction of disease. Similar 
processes may be involved in human ulcerative colitis and blocking various signalling 


































1.1. Innate and Adaptive Immunity 
The mammalian immune system has evolved to allow recognition and elimination of 
pathogens and foreign material (antigens) while maintaining tolerance towards ‘self’ 
components (Davidson 1985; Roitt et al. 2001). The innate immune response precedes 
adaptive immunity following infection or antigen recognition. A number of cell types 
and serum proteins provide immediate protective responses, following contact with 
pathogens. The responses generally triggered by pattern recognition provide stimuli that 
shape the adaptive immune system. Important to the innate response are phagocytic 
macrophages and neutrophils. These cells bind to micro-organisms, internalize and kill 
them (Solomon et al. 1990). Eosinophils are triggered to release components such as 
eosinophil protease (EPO), which target parasites too large to be phagocytosed. They 
also release enzymes that inactivate mast cell products, and therefore decrease 
inflammatory responses (Solomon et al. 1990). Natural Killer (NK) cells are large 
granular lymphocytes involved in recognizing and killing cells infected by intracellular 
pathogens. They have been shown to be the predominant source of IFN-γ produced early 
in the immune response (Scharton and Scott 1993), while NK T cells have been 
identified as major IL-4 producers in innate immunity (Yoshimoto and Paul 1994). 
Furthermore, γδ T cells respond directly to pathogen-associated molecular patterns 
(PAMPS) independent of major histocompatibility complex (MHC) presentation 
(Hedges et al. 2005). 
A number of plasma proteins termed ‘acute phase proteins’ including complement and 
C-reactive protein (CRP) show a dramatic increase early in infection (Roitt et al. 2001). 
Complement is an important serum protein as it can be non-specific and assist innate 
immunity or target pathogens for phagocytosis, killing and presentation to the adaptive 
immune system. 
Although innate immunity has been regarded as a non-specific system, investigations 
have shown a higher degree of specificity for this immune response (Akira and Takeda 
2004). Toll-like Receptors (TLRs), described for their role in insect innate immunity 
against fungal infections (Lemaitre et al. 1996), have been shown to play a crucial role in 
early host defence against pathogens. TLRs, expressed primarily on macrophages and 
dendritic cells (DCs), recognize PAMPS and control the activation of these cells. 
Therefore, they have been described as linking innate recognition of non-self with the 















responses are slower and mediated by T and B cells. Both cells express highly diverse 
antigen receptors that are generated through DNA rearrangement, and respond to a wide 
range of antigens (Akira and Takeda 2004). 
The adaptive immune response is organized around T and B lymphocytes. Since each 
lymphocyte displays a single kind of antigen receptor, the lymphocyte population is 
extremely diverse with an increased probability of recognizing antigen.   Antigen 
recognition is a key to the development of an effective adaptive response. Antigen 
presenting cells (APCs) are seen as the interface between the innate and adaptive 
immune systems. They carry MHC class II molecules, which are important in presenting 
antigens to CD4+ T helper (Th) cells. Antigens in association with MHC I (found on all 
nucleated cells) alert CD8+ cytotoxic T cells to kill the infected cell (Roitt et al. 2001). 
Following interaction with APCs, CD4+ cells are activated and stimulate mononuclear 
phagocytes to increase their killing activity, and B cells to synthesize antigen specific 
antibodies. Appropriate immunological systems are effective against different types of 
infection. Intracellular pathogens induce a cellular immune response characterized by the 
Th1 subset of CD4+ T cells and cytotoxic CD8+ T cells. In contrast, extracellular 
pathogens and allergens induce a humoral immune response, characterized by the Th2 
subset of CD4+ T cells. 
1.1.1. Cytokines 
Cytokines are regulatory proteins secreted by a variety of immune system cells. Most 
cytokines are low molecular weight polypeptides or glycoproteins, which can be induced 
or constitutive homeostatic. Cytokine production is transient and the action radius is 
short (Vilcek 1998). They have an autocrine function, acting on cells that produce them; 
or a paracrine function, acting on surrounding cells (Roitt et al. 2001). The actions of 
cytokines are pleiotropic; which stimulate or inhibit the differentiation, proliferation or 
function of immune cells and modulate inflammatory responses (Vilcek 1998). One 
cytokine can be produced by a variety of cell types and may often have overlapping 
functions on effector cells (Brombacher 2000), whereas a cytokine cascade may result in 
the increase/decrease of other cytokines. Furthermore, gene knockout mouse strains 
provide an essential tool in the analysis of cytokine function. However, compensatory 















1.1.2. T cell differentiation 
The differentiation of T helper cells into Th1 or Th2 subsets in response to infection and 
allergens plays an important role either in conferring immunity or mediating tissue 
damage.  Which T cell subset gains predominance in an immune response depends on; 
(i) the type of antigen presenting cell, (ii) co-stimulatory molecules, (iii) the nature and 
dose of parasite and (iv) the immediate cytokine environment experienced at the time of 
antigen presentation (Onah and Nawa 2000). The cytokine IL-12 drives CD4+ T cell 
differentiation into Th1 cells and induces IFN-γ and IL-2 cytokine release (Figure 1). In 
general, Th1 responses are generated against intracellular pathogens driving protective 
IgG2a and complement-fixing antibodies, macrophage activation, antibody dependent 
cell-mediated cytotoxicity and delayed-type hypersensitivity. Th1 differentiation is 
initiated by signalling through; the T cell receptor (TCR), STAT1 associated cytokine 
receptors and IL-12 (Weaver et al. 2006). STAT1 signalling upregulates the transcription 
factor T-bet (Mullen et al. 2001), which stimulates IFN-γ gene expression and 
upregulates the IL-12 receptor (IL-12Rβ2). Signalling through STAT4 via the IL-12Rβ2 
stimulates expression of IFN-γ and the IL-18 receptor, therefore creating a positive 
feedback.  
A Th2 response driven by IL-4 is necessary for the elimination of helminth infections 
(Urban et al. 1991; Kopf et al. 1993; Svetic et al. 1993; Finkelman et al. 1997). In 
allergic reactions on the other hand, the body develops an exaggerated Th2 response to 
seemingly harmless antigens in genetically predisposed individuals which could lead to 
anaphylactic shock and death (Holgate 1999) (Figure 1). Th2 differentiation is driven by 
TCR and IL-4 receptor alpha (IL-4Rα) signalling via the STAT6 pathway. Together 
these signals upregulate expression of GATA-3 (Ferber et al. 1999). Th1 and Th2 
responses counter regulate each other. STAT1 downregulates Th2 associated GATA-3; 
similarly STAT6 suppresses Th1 development by blocking IL-12Rβ2 expression 
(Weaver et al. 2006). Furthermore, IL-10 downregulates Th1 polarization, while IL-12 





































































Figure 1: T-helper cell differentiation. 
Th1 and Th2 cells are derived from naïve Th0 cells. Th1 differentiation is prompted by IL-12 and IL-18 
(from dendritic cells) and Th2 prompted by IL-4 (from NK, B cells, basophils and γδ cells). TGF-β in 
combination with IL-4 drives the differentiation of Th9 cells directly or ‘reprograms’ Th2 cells to switch to 
IL-9 production. An inflammatory response mediated by TGF-β1 induces Th17 differentiation and a 
regulatory T cell response. Th5 cells are generated from naïve CD4+ T cells by IL-33 in the presence of 
antigen. Products of Th1 and Th2 cells inhibit Th17 differentiation. Red arrows represent cross regulatory 
effects. Illustration adapted from previous publications (Brombacher 2000; Roitt et al. 2001; Tato and 















Although the Th1/Th2 paradigm is widely accepted, it is clear that it does not cover all 
inflammatory responses or autoimmune diseases. Publications have shown a subset of 
CD4+ IL-17-producing cells (Th17), which are stimulated by IL-6, TGF-β1 and IL-23 
and distinct from Th1 or Th2 cells (Bettelli et al. 2006; Mangan et al. 2006). These Th17 
cells are involved in immunity to extracellular bacteria but also mediate autoimmune 
disease (Figure 1). In contrast, IL-6 inhibits the generation of TGF-β1stimulated 
CD4+CD25+Foxp3+ regulatory T cells. Furthermore, a recent publication showed that 
TGF-β ‘reprograms’ Th2 cells to lose their characteristic profile and secrete IL-9 instead. 
With the combination of IL-4, TGF-β can drive the differentiation of cells producing IL-
9 directly. This differentiation was shown to be dependent on STAT6 signalling. These 
cells are distinct from other CD4+ T cell subsets and have been described as Th9 cells 
(Veldhoen et al. 2008). A role has also been described for IL-33; signalling via the ST2 
pathway and MyD88, which induces CD4+ T cells to secrete IL-5 independently of IL-4 
or STAT6. IL-33 administration induces IL-5 producing ‘Th5’ cells and exacerbates 
allergen-induced airway inflammation in wild type and IL-4 knockout mice (Schmitz et 
al. 2005; Kurowska-Stolarska et al. 2008). 
The T cell paradigm, as illustrated in Figure 1, can therefore be summarized as; 
differentiation into Th1 by IFN-γ, Th2 by IL-4, Th17 by IL-23/TGF-β1/IL-6 and Treg by 
TGF-β1. However, the possibility of other T helper subsets such as Th5 and Th9 should 
not be excluded. It is unclear how many more effector T cell subsets there may be and 
what their role would be in controlling or causing disease. These results illustrate another 
exciting layer of complexity to the cytokine network induced by infection, opening new 
possibilities for the development of treatments.  
1.2. Interleukin-4 and Interleukin-13 
1.2.1. Interleukin-4 
Mouse IL-4 is a glycoprotein with a molecular weight of 14-19 kDa (Yokota et al. 1986), 
localized on chromosome 11 together with genes for IL-5 and IL-13 (Morgan et al. 
1992). The human IL-4 gene consists of four exons and three introns spanning 10kb 
(Arai et al. 1989). Innate sources of IL-4, such as basophils (Min et al. 2004), mast cells 
(Plaut et al. 1989), γδ T cells (Ferrick et al. 1995), NK1.1+ T cells (Yoshimoto and Paul 
1994), eosinophils (Sabin et al. 1996) and conventional T cells (Launois et al. 1995; 















4-independent Th2 differentiation has also been described (Noben-Trauth et al. 1997; 
Brombacher 2000; Jankovic et al. 2000; Mohrs et al. 2000; Ritz et al. 2002; Cunningham 
et al. 2004). Furthermore, IL-4 has been shown not to be essential for Th2 
differentiation, as demonstrated in IL-4Rα and STAT6-deficient mice that are able to 
generate sufficient numbers or Th2 cells in response to nematodes (Noben-Trauth et al. 
1997; Finkelman et al. 2000). IL-4 increases the expression of genes such as the low 
affinity IgE receptor (CD23) (Defrance et al. 1987), IL-4R (Ohara and Paul 1987), MHC 
class II (Noelle et al. 1984), CD80 and CD86 (Stack et al. 1994). IL-4 also induces 
isotype switching to IgE and IgG1 in activated B cells while suppressing the synthesis of 
IgM, IgG2a and IgG2b (Vitetta et al. 1985; Coffman et al. 1986; Snapper et al. 1988). 
1.2.2. Interleukin-13 
IL-13 is a 10-14 kDa immunoregulatory cytokine first described as a protein 
preferentially produced by activated mouse Th2 cells (Brown et al. 1989; Minty et al. 
1993; Hershey 2003). Mouse IL-13 is localized on chromosome 11 together with genes 
for IL-3, IL-4, IL-5 and GM-CSF. The human IL-13 gene consists of four exons and 
three introns, localized 12 kb upstream of the gene encoding IL-4 on chromosome 5q31 
(McKenzie et al. 1993; Smirnov et al. 1995). IL-13 is produced by T cells, NK T cells, 
mast cells, basophils, dendritic cells and NK cells (McKenzie et al. 1993; de Saint-Vis et 
al. 1998; Hoshino et al. 1999; Heller et al. 2005). IL-13 has distinct functions on a wide 
variety of cell types with diverse biological activities. A review by Thomas Wynn 
summarizes the effector functions of IL-13 (Wynn 2003). Essentially, IL-13 regulates 
gastrointestinal parasite expulsion, first shown in studies with Nippostrongylus 
brasiliensis (McKenzie et al. 1998; Urban et al. 1998) and intracellular parasitism in 
BALB/c mice susceptible to Leishmania major (Noben-Trauth et al. 1999). Furthermore, 
IL-13 regulates various aspects of inflammatory diseases of the lung shown in disease 
models of pulmonary inflammation (Chiaramonte et al. 1999; Blease et al. 2001), asthma 
(Grunig et al. 1998; Wills-Karp et al. 1998; Zhu et al. 1999) and anaphylaxis (Fallon et 
al. 2001). Functionally, IL-13 promotes proliferation of B cells, class switching to IgG4 
and IgE, induces the expression of surface antigens (CD23 and MHCII), inhibits pro-
inflammatory mediators by monocytes and macrophages, effects eosinophil function and 















1.2.3. IL-4 and IL-13 receptor complexes. 
Both IL-4 and IL-13 cytokines use the IL-4Rα chain as a component of their receptors 
(Figure 2). This was shown in mice treated with anti-IL-4Rα antibodies or IL-4 
antagonists (Aversa et al. 1993), which specifically blocked responses of both IL-4 and 
IL-13 (Aversa et al. 1993; Zurawski et al. 1993; Zurawski et al. 1995; Hilton et al. 
1996). The IL-4Rα consists of a 140-kDa IL-4Rα chain which is a component of both the 
type I and type II IL-4 receptors. The IL-4Rα is expressed in relatively low numbers on 
numerous cell types (Ohara and Paul 1987; Lowenthal et al. 1988; Nelms et al. 1999). 
The type I IL-4 receptor results from association of IL-4Rα with the gamma common 
(γc) chain, which is also a component of the receptors for IL-2, IL-7, IL-9, IL-15, and IL-
21 (Leonard and Lin 2000; Hershey 2003). The type II IL-4/IL13 receptor results from 
association of IL-4Rα with IL-13Rα1. 
The type II receptor is composed of the IL-4Rα chain and the 65-70 kDa IL-13Rα1 chain 
and serves as an alternative receptor for IL-4 (Figure 2). By itself, IL-13Rα1 binds IL-13 
with low affinity but when paired with IL-4Rα, it binds IL-13 with high affinity and 
forms a functional unit that signals (Miloux et al. 1997; Hershey 2003). IL-13Rα1 is 
expressed on many cell types including; B cells, monocytes, macrophages, basophils, 
mast cells and endothelial cells with the exception of human or mouse T cells (Gauchat 
et al. 1997; Graber et al. 1998; Hershey 2003). Although IL-13 signals via the IL-13Rα1, 
it has a higher binding affinity to the α2 chain of the IL-13 receptor (IL-13Rα2), which 
has previously been considered as a decoy receptor for IL-13 with no signal transduction. 
IL-13Rα2 is a 55-60 kDa protein closely related to IL-13Rα1 except that the cytoplasmic 
domain has no signalling motifs or binding sequences for signalling molecules (Colotta 
et al. 1994; Donaldson et al. 1998). However, recent publications have highlighted a 
possible signalling pathway for IL-13 through the IL-13Rα2. IL-13 signalling through 
the IL-13Rα2 was shown to be involved in the induction of TGF-β1 production or 
mediating fibrosis in a chronic mouse model of Crohn’s disease (Fichtner-Feigl et al. 
2006; Fichtner-Feigl et al. 2008). These studies suggest that IL-13Rα2 signalling could 
be an important therapeutic target for the prevention of inflammatory diseases. 
In addition to cell surface receptors, soluble forms of both IL-4Rα and IL-13Rα2 exist 
and are suggested to bind IL-4 and IL-13 with high affinity as non-signalling monomers. 
Therefore, the soluble receptors can act as competitive inhibitors of IL-4 and IL-13 and 















1.2.4. Mechanisms of IL-4 and IL-13 signalling 
IL-4 and IL-13 not only share common subunits, they also share common signalling 
pathways (Figure 2). The components of both receptor complexes are associated with 
Janus kinases (JAK). JAK1 has been proposed to associate with the IL-4Rα chain (Yin et 
al. 1994), γc with JAK3 (Russell et al. 1994; Nelms et al. 1999) and IL-13Rα1 with 
JAK2 (Murata et al. 1996). The signal transducer and activator of transcription 6 
(STAT6) is recruited to the phosphorylated IL-4Rα where it also becomes 
phosphorylated by JAKs (Nelms et al. 1999). Studies using STAT6-deficient mice have 
determined that IL-13 signalling uses the JAK/STAT6 pathway (Takeda et al. 1996). 
Regulatory phosphatases (for negative regulation of signalling) and insulin receptor 
substrate (IRS) are other groups of signalling molecules recruited to the IL-4Rα chain 
(Nelms et al. 1999). Until recently the IL-13Rα2, which binds IL-13 with high affinity, 
was thought to relay no signal (Kawakami et al. 2001). Fichtner-Feigl et. al. have shown 
that IL-13 signalling through IL-13RαI/IL-4Rα together with TNF-α signalling through 
TNFR1, up regulates IL-13Rα2 surface expression on macrophages. IL-13 binding this 















































Figure 2: IL-4 and IL-13 receptor complexes. 
IL-4 interacts with the type I (IL-4Rα and γc) and type II (IL-4Rα and IL-13Rα1) receptor complexes. 
These receptors then signal through the JAK1/STAT6 pathway. IL-13 interacts with the type II receptor 
complex and with IL-13Rα2.  IL-13 also induces production of TGF-β in macrophages in two steps. IL-
13Rα2 surface expression is upregulated in response to a combination of IL-13 and TNF-α. IL-13 binds to 
IL-13Rα2 with high affinity and activates AP-1 to induce secretion of TGF-β. Illustration adapted from 















1.3. Inflammatory Bowel Disease 
Ulcerative colitis (UC) and Crohn’s disease (CD) are chronic, immunologically mediated 
disorders collectively referred to as human inflammatory bowel disease (IBD). For UC 
long term inflammation and destruction eventually leads to the removal of the large 
intestine or colectomy. Although the incidence of both CD and UC is beginning to 
stabilize in high-incidence areas, cases are increasing in low-incidence areas including, 
southern Europe, Asia and parts of the developing world (Loftus 2004). UC and CD 
share many clinical and pathological characteristics, but they have immunological and 
disease processes which are distinct for each disease (Podolsky 2002; Bouma and 
Strober 2003; Targan and Karp 2005; Sartor 2006a). UC can be distinguished from CD 
by the nature of inflammatory changes in the gut. UC is restricted to the superficial 
epithelial layer of the colon, while CD is found throughout the intestine affecting 
multiple layers (Bouma and Strober 2003). Although the pathogenesis of UC and CD is 
unclear, it is suggested that the intestinal mucosal immune system is disrupted leading to 
a loss of tolerance to commensal bacterial in genetically predisposed individuals 
(Podolsky 2002; Bouma and Strober 2003). Environmental triggers are also necessary to 
initiate or reactivate disease expression. Defects in bacterial antigen sampling leads to an 
inappropriate immune response with activation of dendritic cells and an overly 
aggressive acquired T cell immune response. Immunological events driven by a cascade 
of cytokines finally result in tissue damage including; loss of epithelial and goblet cells, 
oedema and ulceration (Podolsky 2002; Sartor 2006a). 
1.3.1. Classification and features of inflammatory bowel disease 
Ulcerative colitis and Crohn’s disease have many similarities but can be distinguished by 
clinical, pathological and immunological features. However, in as many as 10 percent of 
patients with IBD that is limited to the colon, it may not be possible to distinguish UC 
from CD initially. These patients are considered to have indeterminate colitis (Podolsky 
2002; Bouma and Strober 2003). Table 1 summarizes some of the symptoms and 
























Clinical features   
Fever Fairly common Common 
Abdominal pain Varies Common 
Diarrhoea Very common Fairly common 
Rectal bleeding  Very common Fairly common 
Weight loss Fairly common Common 
Signs of malnutrition Fairly common Common 
Perianal disease Absent Fairly common 
Abdominal mass Absent Common 
   
Site   
Colon Exclusively 2/3 of patients 
Ileum Never 2/3 of patients 
Jejunum Never Infrequent 
Stomach or duodenum Never Infrequent 
Oesophagus Never Infrequent 
   
Intestinal complications   
Stricture Unknown Common 
Fistulas Absent  Fairly common 
Cancer Common Fairly common 
   
Endoscopic finding   
Friability Very common Fairly common 
Aphthous and linear ulcers Absent  Common 
Cobblestone appearance Absent  Common 
Pseudopolyps Common Fairly common 
Rectal involvement Very common Fairly common 
   
Radiologic findings   
Distribution Continuous Discontinuous, segmented 
Ulceration Fine, superficial Deep, with submucosal 
extension 
Fissures Absent  Common 
Strictures and fistulas Rare Common 
   
Histology Superficial layers of bowel wall All layers of bowel wall 
 Infiltration of lymphocytes and 
neutrophils 
Infiltration of lymphocytes and 
macrophages 
 Loss of goblet cells Presence of granulomas 
 Ulceration Ulceration 
 Crypt abscesses Submucosal fibrosis 










(Left) Histology section of a patient 
with UC showing mucosal inflamma-
tion and erosion.  
(Right) Histology section of a patient 
with CD showing inflammation ex-
tending the full thickness of the wall 
from the mucosa to the serosa. 
Granulaomas (G) can be seen 
towards the serosal surface. 
















1.3.2. Factors contributing to ulcerative colitis 
Genetics 
Although evidence suggests UC is linked to genetic factors, there is no single gene 
responsible for the disease. Different genetic abnormalities can lead to similar clinical 
features of intestinal inflammation. Several genes with increased association among 
patients with UC have been demonstrated. The MHC class II region on chromosome 6 
(known as IBD3) has been associated with UC (Toyoda et al. 1993; Satsangi et al. 1996; 
Targan and Karp 2005) as have IBD2 and IBD6 loci. Recently, researchers performed a 
genome-wide study on UC patients to identify other genes involved in the disease. Genes 
of interest on chromosome 1p36 were, the ring finger protein 186 (RNF186), OTU 
domain containing 3 (OTUD3), and phospholipase A2 group IIE (PLA2G2E). Genes of 
interest on chromosome 12q15 were the IFN-γ, IL-26 and IL-22 genes playing a role in 
inflammation and the immune response (Imielinski et al. 2009). Furthermore, another 
recent study has shown that a missense error in the membrane-bound transcription factor 
peptidase site 1 (S1P)-encoding gene (Mbtps1) causes enhanced susceptibility to dextran 
sodium sulfate (DSS), a mouse model of UC (Brandl et al. 2009). 
Commensal microbial stimulants 
Although genetic background is proving to be an important requisite for UC, 
environmental factors such as commensal bacteria and persistent infection also influence 
genetic susceptibility. In contrast to normal patients, T cells from patients with UC or 
CD proliferate in response to both autologous and heterologous faecal bacteria 
(Duchmann et al. 1995; Sartor 2006b). Furthermore, the presence of bacterial 
overgrowth and relative effectiveness of antibiotic treatment suggests that microbes may 
be responsible for inflammation in the genetically predisposed mucosa (Targan and Karp 
2005). In experimental colitis, mice are generally protected from disease when kept in a 
germ-free environment, suggesting that normal flora plays a role in initiating 
inflammation either by functioning as adjuvants or antigens. Adjuvants are responsible 
for activating innate immune responses including APCs and antigens which stimulate the 
clonal expansion of T cells via the T cell receptor (Sartor 1997; Podolsky 2002; Bouma 
and Strober 2003).  
1.3.3. Mouse models of Inflammatory Bowel Disease 
Animal models of intestinal inflammation are essential in our understanding of IBD. 















to study pathological mechanisms and the effect of emerging therapeutic strategies. 
Many different factors induce intestinal inflammation in mice but the final common 
pathway eventually resolves into a Th1 or Th2 response (Elson et al. 1995; Strober et al. 
2002; Elson et al. 2005; Wirtz and Neurath 2007). Table 2 lists a few animal models 
used to study Th1 and Th2 mediated mucosal inflammation (adapted from Strober et al. 
2002). The Th1 pathway has been shown to be predominant in IBD with most models 
developing an excessive IFN-γ response. This Th1 bias could be due to inflammation 
being driven by antigens from the intestinal microflora, which initiates innate immune 
responses mediated by TLRs. TLRs generally activate NF-κβ which leads to IL-12 
production and a polarized Th1 response (Takeda et al. 2003; Strober and Fuss 2006). 
Although, CD4+ Th1 cells mediate disease in most IBD models and resemble Crohn’s 
disease, CD4+ Th2-mediated colitis models resembling ulcerative colitis have also been 









TNBS colitis TCR-α chain deficiency 
SCID-transfer colitis Oxazolone colitis 
TCR Tg mice with lymphopenia WASP deficiency 
IL-10 deficiency colitis DSS colitis * 
IL-10 signalling defects (CRF2-4 deficieny) TNBS colitis in BALB/c mice * 
Tgε26 mice  
TNFARE mice (TNF-α overproduction)  
C3H/HeJBir mice  
Gi2α-deficient mice  
Samp1/Yit mice  
T-bet Tg mice  
STAT4 Tg mice  
TGF-β RII dominant-negative Tg mice  
HLA-B27 Tg rats  
Mdrla-deficient mice  
DSS colitis  
IL-7 Tg mice 
 
 















It has been shown that low affinity interactions between antigen and TCR favour Th2 
differentiation, therefore the small amounts of IL-4 required to drive a Th2 response are 
produced (Pfeiffer et al. 1995; Guo et al. 2004; Strober and Fuss 2006). Previous studies 
using hapten-induced mouse models of colitis have shown that the genetic background of 
a mouse influences the outcome of T cell responses. Trinitrobenzene sulphonic acid 
(TNBS)-induced colitis mediates a Th1-driven inflammation which resembles CD in 
SJL/J mice, but a mixed Th1/Th2 disease in BALB/c mice (Neurath et al. 1995; Dohi et 
al. 1999). Oxazolone-induced colitis mediates a Th2-driven inflammation which 
resembles UC in SJL/J, BALB/c and C57BL/10 mice (Boirivant et al. 1998; Heller et al. 
2002; Kojima et al. 2004; Fichtner-Feigl et al. 2006; Weigmann et al. 2008). However, 
C57BL/6 mice have a tendency towards Th1 immune responses (Charles et al. 1999) and 
require pre-sensitization with oxazolone to induce a Th2 response (Iijima et al. 2004). 
Chemically induced models of colitis are widely accepted and used as IBD animal 
models and although they have limitations, they resemble important histological and 
immunological aspects of human IBD (Wirtz and Neurath 2007) (see Figure 3). TNBS 
and oxazolone are both covalently reactive reagents which are believed to induce a T 
cell-mediated response against hapten-modified luminal antigens. Dextran sodium 
sulphate (DSS) is a chemical directly toxic to colonic epithelial cells of the basal crypts 
(Morris et al. 1989; Okayasu et al. 1990; Yamada et al. 1992; Boirivant et al. 1998; 
Wirtz and Neurath 2007).  
TNBS colitis 
As with oxazolone, TNBS dissolved in ethanol with or without skin pre-sensitization 
induces colitis in susceptible mouse strains. Ethanol is required to break the mucosal 
barrier and TNBS or oxazolone is thought to haptenize colonic proteins making them 
immunogenic to the host (Neurath et al. 1995).  TNBS induces an IL-12-mediated Th1-
cell response in SJL/J mice and inflammation that resembles CD (see Figure 3). Disease 
parameters include; inflammation affecting the entire colon, infiltration of lymphocytes 
and macrophages, thickening of the colon wall, ulceration, loss of goblet cells and the 
presence of granulomas (Neurath et al. 1995; Bouma and Strober 2003). Antibodies 
blocking IL-12 not only prevents TNBS colitis but can also successfully treat established 
colitis (Neurath et al. 1995). Furthermore, a crucial role for TNF-α in CD was confirmed 
using TNF-α knockout mice which were protected from TNBS colitis. In contrast, mice 
over-expressing TNF-α developed severe colitis in response to TNBS treatment (Neurath 





















inflammation such as 
oxazolone colitis in mice
Crohn’s disease
Th1-mediated 
inflammation such as 
TNBS colitis in mice
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IL-4 and other cytokines? IL-12 (IL-23?)
Untreated colon
 
Figure 3: Th1 and Th2-mediated colitis. 
Trinitrobenzene sulphonic acid (TNBS) and oxazolone give rise to different forms of colitis when 
administered intrarectally together with ethanol (an agent that temporarily decreases epithelial barrier 
function). These colitides are strain-specific and genetically determined. TNBS that is administered to 
SJL/J or C57BL/10 mice elicits a classical T helper (Th1)-cell response owing to IL-12-mediated 
production of IFN-γ by CD4+ T cells. The result is a transmural inflammation that resembles Crohn’s 
disease. By contrast, oxazolone induces a Th2-cell response in SJL/J, C57BL/10 and BALB/c mice that is 
mediated by natural killer T cells that produce IL-13. The result is a superficial inflammation that 

















Oxazolone colitis was first described by Boirivant and colleagues in 1998 and has since 
been widely accepted by other researchers as an IL-4/IL-13-mediated Th2 model for 
human ulcerative colitis (see Figure 3) (Boirivant et al. 1998). The model was 
established in highly susceptible SJL/J mice and then C57 background strains for the 
benefit of using genetically manipulated mice (Heller et al. 2002; Nieuwenhuis et al. 
2002). Subsequently, oxazolone colitis has been successfully induced in BALB/c mice 
and the tissue damage (although transient) reflects that of human UC. Disease parameters 
include; weight loss, inflammation affecting the distal colon, infiltration of lymphocytes 
and granulocytes, patchy ulceration, loss of goblet cells, epithelial cell loss and oedema. 
The colitis is superficial as outer muscle layers show no evidence of inflammation 
(Kojima et al. 2004). Blocking IL-4 (Boirivant et al. 1998),  IL-13 (Heller et al. 2002) or 
using IL-13 gene-deficient mice (Weigmann et al. 2008) has been shown to ameliorate 
or prevent disease induction, whereas antibodies against IL-12 cause severe pancolitis 
affecting both the distal and proximal colon (Boirivant et al. 1998). 
DSS colitis 
Oral administration of DSS polymers has been shown to induce acute and chronic colitis 
in mice by affecting the integrity of the mucosal barrier. Early lesions occur mainly in 
the distal colon and are associated with bloody diarrhoea, ulcerations and granulocyte 
infiltration (Okayasu et al. 1990; Wirtz et al. 2007; Wirtz and Neurath 2007). SCID mice 
also develop acute colitis in response to DSS, indicating that T and B cells are not 
required. Therefore, the acute DSS model is useful to study innate immune mechanisms 
of colitis (Dieleman et al. 1994). Another study by Dielmann et. al.  showed that the 
chronic phase of DSS-induced colitis is characterized by both Th1 and Th2  cytokine 
profiles, suggesting that chronic immune activation is mediated by both populations of 
Th cells (Dieleman et al. 1998). When DSS is administered for several cycles, 
susceptible mouse strains develop chronic colitis and addition of the colon carcinogen 
azoxymethane (AOM) results in inflammation-associated colorectal cancer (Tanaka et 
al. 2003). As patients with UC have an increased risk of developing colon cancer (Jess et 
al. 2006) this model is useful to study the mechanisms linking inflammation to colon 















1.3.4. Immune response in human ulcerative colitis 
The function of the mucosal immune system is to protect the epithelial barrier from 
invasion by microbes but avoid responding to commensal bacteria or food proteins. 
Tolerance in normal hosts is mediated by regulatory T cells, B lymphocytes, NKT cells 
and dendritic cells. Essentially, antigen presented to T cells with low levels of 
costimulation and immunoregulatory cytokines induce tolerance (Brandtzaeg 1996). 
Upon defective control mechanisms, an enhanced uptake of commensal bacteria 
adjuvants and antigens drive chronic intestinal inflammation resulting in IBD (Nagler-
Anderson 2001; Sartor 2006a). This defect could be due to transient infection, ingested 
toxin or genetic susceptibility of the host. Finally, immunoregulatory defects or 
continued antigenic stimulation lead to pathogenic Th1 or Th2 immunological responses 
(Sartor 2006b).  
In human UC the CD4+ subset responsible for disease pathogenesis is not completely 
defined, but based on the histopathological resemblance to Th2-mediated mouse models 
of mucosal inflammation, pathology is accepted to be mediated by an atypical Th2 
response (Boirivant et al. 1998; Mizoguchi et al. 1999; Elson et al. 2006). Increased 
production of Th2 cytokines, such as IL-5 and IL-13 have been found in lamina propria 
cells from UC patients, but IL-4 is not increased (Fuss et al. 1996; Heller et al. 2005). 
However, a study using the oxazolone mouse model shows IL-4 to be important in 
disease induction in SJL/J mice, with IL-13 acting later in disease progression and 
chronicity (Heller et al. 2002). Therefore, diagnosis of human UC might be after the IL-4 
levels have been superseded by increased IL-13. 
Due to the increased epithelial permeability with excessive antigen exposure, distorted B 
cell differentiation leads to an immunological imbalance and second line of mucosal 
defence. This includes the production of IgG antibodies which exhibit proinflammatory 
properties. Therefore, there is an increase in antigen penetrating the epithelial barrier, 
attraction of inflammatory cells and release of inflammatory mediators (Brandtzaeg et al. 
2006). In UC patients, there is an increase in IgG antibodies and the cells which produce 
them (Hibi et al. 1990; Onuma et al. 2000). However, it is not certain if antibodies play a 
role in the pathology of UC or if B cells have a regulatory role rather than pathogenic 















Finally, cytokine production initiates a cascade of inflammatory events which results in 
tissue damage. Although many aspects of this response remain to be understood, studies 
have highlighted a role for IL-13 acting directly on epithelial cells. Heller et. al. show 
that IL-13 impairs epithelial barrier function by affecting epithelial apoptosis and tight 
junctions leading to the severe destructive inflammation seen in patients with UC (Heller 
et al. 2005). 
1.3.5. Animal models suggest immune mechanisms for human ulcerative colitis 
Mouse models of intestinal inflammation are valuable tools in understanding the 
pathogenesis of IBD in humans. Figure 4 illustrates some of the mechanisms underlying 
UC created by combining information from animal and human studies. The importance 
of Th2 cytokines was first demonstrated with studies showing that IL-4 deficiency or 
neutralizing IL-4 protected SJL/J mice from oxazolone colitis (Boirivant et al. 1998; 
Iijima et al. 2004). As mentioned above, IL-4 was shown to be important in initiating 
colitis but is superseded by IL-13 production in chronic oxazolone models. Further 
studies have suggested that IL-13 production by NKT cells is the main inducer of disease 
(Heller et al. 2002). Blocking IL-13 or depleting NKT cells protects mice from 
developing inflammation. The importance of NKT cells in oxazolone-induced colitis was 
also demonstrated in a study using mice deficient in the Epstein–Barr virus-induced gene 
3 (EBI3). These mice exhibit normal numbers of naïve and mature CD4+, CD8+ T cells 
and B cells but significantly reduced numbers of invariant NKT cells (iNKT). EBI3-/- 
mice were resistant to oxazolone-induced colitis with reduced IL-4 suggesting EBI3 to 
play a critical role in the induction of type 2 immune responses possibly mediated 
through iNKT cell function (Nieuwenhuis et al. 2002).  
Another Th2 cytokine recently shown to be of interest in UC is IL-6. Essentially, the 
nuclear factor of activated T cells (NFATc2) is upregulated in human UC patients and 
oxazolone-treated mice. NFATc2 deficiency in mice suppresses oxazolone-induced 
colitis with reduced production of IL-6 and IL-13 by mucosal T cells. IL-6-deficient 
mice were protected from oxazolone colitis suggesting a regulatory role for NFATc2 in 
colitis in an IL-6-dependent manner (Weigmann et al. 2008). Furthermore, IL-25 has 
been shown to be important in controlling immunity in the gut and could prove 
interesting in UC studies (Owyang et al. 2006). IL-25 induces (i) epithelial cell 
hyperplasia (ii) mucus production and (iii) infiltration with granulocytes; associated with 







































Figure 4: Pathogenesis of ulcerative colitis. 
Commensal bacteria products stimulate epithelium or the mucosal immune system by penetration of the 
mucosal barrier. Activation of antigen presenting cells (APCs) or direct stimulation of NKT cells results in 
a type 2 response. NKT cells could have a cytotoxic effect on the epithelium directly or produce IL-13 
which is toxic to epithelial cells. Recent studies have proposed roles for IL-6 and IL-25 in driving Th2 
responses in UC (adapted from Podolsky 2002; Bouma and Strober 2003; Targan and Karp 2005; Owyang 
















Considering the importance of IL-13 signalling in both human UC and mouse oxazolone 
colitis, studies are investigating the role of IL-13Rα2 (the high affinity receptor for IL-
13) in colitis models (Fichtner-Feigl et al. 2006; Fichtner-Feigl et al. 2008). As the 
cytoplasmic region of murine IL-13Rα2 has no obvious signalling motif, it was 
previously thought to be a decoy receptor for IL-13 (Donaldson et al. 1998; Wynn 2003). 
Fichtner-Feigl et. al. demonstrated the signalling pathway for IL-13Rα2 through AP-1 to 
induce TGF-β production (see Figure 2). Signalling through IL-13Rα2 is dependent on 
TNF-α. Blocking TNF-α leads to reduced TGF-β production in oxazolone-induced colitis 
with inflammation no longer limited to the distal colon (Fichtner-Feigl et al. 2006).  
1.4. Therapeutic strategy for ulcerative colitis 
Current treatment strategies for UC use broad anti-inflammatory drugs and are not 
specific for the disease. 5-Aminosalicylates (5-ASA) are bowel-specific anti-
inflammatory drugs, considered a first-line therapy for mild to moderately active UC and 
have been in use since the forties (Dick et al. 1964; Sandborn et al. 2009). Other 
treatments include; corticosteroids, azathioprine/6-mercaptopurine (reduce lymphocyte 
numbers), intravenous cyclosporine (immunosuppressant) and colectomy (Bouma and 
Strober 2003). Animal models of disease provide vital information on the immune 
mechanisms involved in UC and could assist in finding a new approach to specific 
treatment strategies. Using the TNBS colitis mouse model resembling human CD, it was 
established that IL-12 driven Th1 cell responses were responsible for inducing 
inflammation. Anti-IL-12 antibodies successfully prevented and treated disease 
development in mice. Based on these studies, anti-IL-12 was used in a trial as a 
therapeutic agent in humans with CD, showing promising results (Mannon et al. 2004). 
UC has been defined as a Th2-mediated inflammation which leads to the possibility that 
Th2 cytokine inhibitors, such as IL-13-specific antibody, might be a useful target to treat 
this kind of IBD.  Another cytokine of interest is IL-6, shown to be increased in human 
UC (Atreya et al. 2000). IL-6-deficient BALB/c mice are protected from oxazolone-
induced colitis suggesting that this cytokine is essential in driving disease (Weigmann et 
al. 2008). 
1.5. Cell-specific gene targeting 
The IL-4Rα is found on haematopoietic, endothelial, epithelial, muscle, fibroblast, 
hepatocyte and brain tissue (Nelms et al. 1999). In order to study the effects of IL-4 or 















accomplished by using Cre/loxP recombination (see Figure 5). Cyclization recombinase 
(Cre) inserted downstream of the promoter recognises a pair of loxP binding sites 
flanking the gene of interest (Exon7 through 9 of IL-4Rα). Cre-recombinase brings the 
two loxP sites together, removing the intervening DNA which encodes the 
transmembrane, soluble and extra cellular membrane proximal regions (Nagy 2000). To 
specifically target IL-4Rα deletion on T cells (LckcreIL-4Rα-/lox), Cre-recombinase 
expression was driven using the T cell-specific Lck promoter (Gu et al. 1994; 
Radwanska et al. 2007). Lck protein tyrosine is a kinase involved in the T cell signal 
transduction pathway (Janeway and Travers 1996). For novel B cell-specific IL-4Rα-
deficient mice (mb1creIL-4Rα-/lox), Cre-recombinase was driven by the mb1 promoter. 
The mb1 gene encodes the Ig-α signaling subunit of the B cell antigen receptor (Hobeika 

















Figure 5: IL-4Rα gene locus and targeted deletion.  
Introduction of a neo/tk selection cassette flanked by two loxP sites (yellow arrowhead), and one loxP site 
5’ of exon 10 resulted in the generation of the conditional “floxed” mouse after Cre-mediated 
recombination. An intercross between the floxed strain and Lckcre, or mb1cre knockin strain facilitated the 
generation of T or B cell-specific IL-4Rα-deficient mice. Numbers indicate exons of the IL-4Rα; B, E and 
X, restriction sites for BamHI, EcoRI and XhoI (described by Herbert et al. 2004).  
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1.6. Objectives  
 
• To establish a chemically-induced (oxazolone) mouse model of ulcerative colitis in 
BALB/c mice. 
• To investigate the role of Th2 cytokines in oxazolone-induced colitis by using 
BALB/c mice deficient in genes for IL-4, IL-13 and IL-4Rα or overexpressing IL-
13. 
• To determine the role of IL-4 responsive B cells and IgE production in oxazolone 
colitis. 
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IL-13 signals independently of IL-4 receptor-alpha to 

















Ulcerative Colitis (UC) is a human Inflammatory Bowel Disease (IBD) associated with 
chronic inflammation of the gastrointestinal tract. Although UC is associated with a 
Th2/Type 2 immune response, current treatment strategies use broad anti-inflammatory 
drugs which are aspecific for the disease. A mouse model resembling UC is oxazolone-
induced colitis. In this model interleukin (IL)-4 and IL-13 production are important 
pathological factors and neutralizing these cytokines prevents or ameliorates disease 
significantly. As many aspects of the mechanisms involving these Th2 cytokines in 
colitis remain undefined, we used mice deficient in IL-4/IL-13 or their shared receptor 
chain, IL-4 receptor-alpha (IL-4Rα), to further dissect their role in oxazolone-induced 
colitis. 
Treatment of wild type BALB/c mice with oxazolone induced rapidly developing colitis 
confined to the distal colon with characteristics resembling human UC. Disease 
symptoms were exacerbated in IL-4Rα-/- mice with increased weight loss, mortality, 
inflammation and immunopathological symptoms. This was in contrast to IL-4/IL-13 
double-deficient mice which were protected from colitis. Removing IL-13 production 
from IL-4Rα-/- mice, by using IL-4Rα/IL-13 double-deficient mice, reversed the 
susceptible phenotype to protection. Together these data strongly suggest that IL-13 
mediates susceptibility in an IL-4Rα independent manner. Recent evidence shows that 
the IL-13 receptor-alpha 2 (IL-13Rα2), previously believed to be a decoy for IL-13 only, 
is able to transmit a signal via IL-13. Our results support this and may suggest that IL-13 
signalling through IL-13Rα2 plays an important role in mediating disease in oxazolone-


















Ulcerative colitis (UC) is a human Inflammatory Bowel Disease (IBD) associated with 
chronic inflammation of the gastrointestinal tract. Although the pathogenesis of UC is 
unclear, it is suggested that the intestinal mucosal immune system is disrupted leading to 
loss of tolerance to commensal bacteria in genetically predisposed individuals. UC in 
humans is believed to be a Th2-mediated disease (Podolsky 2002; Bouma and Strober 
2003; Targan and Karp 2005). In mice, treatment with the haptenating agent oxazolone 
(oxa) induces colitis limited to the distal half of the colon with histological features 
resembling human UC. Oxazolone colitis exhibits a Th2 profile in mice with increased 
levels of IL-4, IL-5 and IL-13 (Boirivant et al. 1998; Kojima et al. 2004; Wang et al. 
2004). Previous studies highlight the importance of IL-4 and natural killer (NK) T cells 
producing IL-13 in oxazolone-induced colitis (Boirivant et al. 1998; Heller et al. 2002). 
However, considering the heterogeneity of UC, many aspects of the mechanisms 
involving IL-4 and IL-13 and the receptors through which they signal remain undefined. 
The importance of Th2 cytokines, in particular IL-13 in oxazolone colitis was first 
highlighted in a study by Heller and colleagues. IL-13 production by NK T cells was 
identified as the main inducer of disease in C57BL/10 mice (Heller et al. 2002). 
Subsequently, restimulation of colonic epithelial cells isolated from UC patients also 
demonstrated increased levels of IL-13 production compared with control patients 
(Heller et al. 2005; Fichtner-Feigl et al. 2006). In further studies, IL-13 was described as 
a key effector cytokine in UC acting on epithelial cell function and initiating apoptosis 
(Heller et. al. 2005). The addition of IL-13 in vitro to HT-29 epithelial cell monolayers 
led to an increased expression of the pore-forming tight junction protein claudin-2. 
Increased expression of this protein is associated with increased epithelial barrier 
permeability. As a consequence, small antigens enter the gut and the loss of ions and 
water into the intestinal lumen leads to diarrhoea.  These results suggest that changes in 
barrier function in human UC are not only due to NK T cell cytotoxicity on epithelial 
cells but also because of the subtle changes induced by IL-13 (Heller et al. 2005).  
Furthermore, recent studies have shown IL-13-/- BALB/c mice to be protected from 
oxazolone colitis, confirming the important role of IL-13 in mediating colitis in BALB/c 
mice (Weigmann et al. 2008). Neutralizing IL-4 in SJL/J mice (Boirivant et. al. 1998) or 
IL-4 deficiency in C57BL/6 mice (Iijima et. al. 2004) also protects mice against the 















suggest a major role for IL-4 receptor-alpha (IL-4Rα) in UC. However, there are no 
studies using IL-4Rα gene-deficient mice in the oxazolone model. In this study, we 
adopted an oxazolone-induced model for UC in BALB/c and IL-4Rα-/- mice (Mohrs et al. 
1999), as well as IL-4/IL-13-/- mice in order to define a role for IL-4 and IL-13 signalling 
through IL-4Rα in disease pathology. 
Our data confirms previous studies showing the importance of IL-4 and IL-13 production 
in oxazolone-induced colitis. However we show for the first time that blocking IL-4 and 
IL-13 signalling via the IL-4Rα using mice deficient for this receptor (IL-4Rα-/-) does not 
protect mice from colitis. In fact IL-4Rα-/- mice develop exacerbated pathology with 
significantly higher mortality than oxazolone-treated BALB/c mice. These data suggest a 
regulatory role for IL-4Rα in oxazolone colitis. We confirm that IL-13 mediates colitis in 
IL-4Rα-/- mice, as disrupting IL-13 but not IL-4 production in wild type and IL-4Rα-/- 
mice rescues them from the pathology associated with oxazolone colitis. This highlights 
a role for IL-4Rα-independent signalling of IL-13 to induce colitis. Recently IL-13 has 
been shown to signal via the IL-13Rα2 by up-regulated expression of the AP-1 
transcription factor. This makes IL-13Rα2 a likely candidate for IL-13-mediated 
oxazolone colitis. We show that IL-13Rα2 is expressed on many cell types in the spleen, 
peritoneal cavity and lymph node and that oxazolone down-regulates this expression in 
neutrophils. Lastly, soluble levels of IL-13Rα2 in serum were significantly reduced in 
mice susceptible to oxazolone colitis. Therefore we highlight the importance of IL-4Rα-
independent signalling of IL-13 in mediating oxazolone colitis and suggest a role for IL-















MATERIALS AND METHODS 
Mice.  
Male BALB/c mice (6-8 weeks old) and IL-4-/- (Noben-Trauth et al. 1996), IL-13-/- 
(McKenzie et al. 1998), IL-4Rα-/- (Mohrs et al. 1999) and IL-13 transgenic (Emson et al. 
1998) mice on a BALB/c background were used in oxazolone colitis experiments. 
Furthermore, IL-4-/-, IL-13-/- and IL-4Rα-/- mice were intercrossed to generate IL-4/IL-
13, IL-4Rα/IL-4 and IL-4Rα/IL-13 double-deficient strains. All mice were housed in 
specific pathogen-free conditions at the University of Cape Town, South Africa and 
experiments were approved by the University’s Animal Ethics Committee. 
Induction of colitis by haptenating agent oxazolone. 
Oxazolone-mediated colitis was induced in BALB/c mice by modifying previously 
described methods (Boirivant et al. 1998; Neurath et al. 2002; Kojima et al. 2004). 
Anesthetized mice were sensitized on the shaved abdomen by application of 3% 
oxazolone (4-ethoxymethylene-2-phenyl-2-oxazolin-5-one; Sigma-Aldrich) in 100% 
ethanol (15 µl) followed 7 days later by intrarectal administration of 1% oxazolone in 
50% ethanol (150µl). Control mice were sensitized and challenged with ethanol only 
(controls were included for all mouse groups used, data not shown). For rectal 
administration, a metal catheter was lubricated and inserted 4cm into the lumen of the 
colon via the anus. After injection of the oxazolone/ethanol solution and removal of the 
catheter, mice were held vertically for 30sec to ensure distribution of the oxazolone 
within the entire colon. Mice were weighed and monitored daily and killed 3 days post-
challenge for immunopathological analyses or 7 days post-challenge for survival studies.  
Disease activity index (DAI). 
Oxazolone treated BALB/c mice develop rapid-onset colitis marked by weight loss and 
distress. To monitor disease progression, mice were weighed and monitored for distress 
and gastrointestinal symptoms 1-2 times daily depending on severity. Weight loss was 
measured as a percentage of starting weight and distress was scored at day 2 post-
challenge according to appearance, clinical signs and natural or provoked behaviour (see 
Table 1 of Appendix A) (Wolfensohn and Lloyd 1998). Mice were scored on a scale of 
0-16 and killed if reaching the most severe score (16) or loosing ≥20% body weight. 
Survival studies were performed with 10 mice/group and the same criteria were 
monitored as mentioned above. Colon length was measured from the anus to the caecum 















Measurement of Myeloperoxidase (MPO) activity. 
MPO activity was analyzed as a marker for neutrophil infiltration in inflamed colon 
tissue. Colon tissue from individual mice was weighed, resuspended in HTAB buffer, 
homogenized and sonicated for 20 pulses at 9watts. After centrifugation for 10min at 
10000rpm, the supernatants were collected and added to a 96 well maxisorp microtitre 
plate (Nunc, Reskilde, Denmark) in serial dilutions. A horseradish peroxidase (HRP) 
standard (Sigma, Steinheim, Germany) was added to the plate at a starting concentration 
of 0.25U with 3-fold serial dilutions to quantify MPO activity. O-dianisidine was added 
and after incubation for 10min at 35°C, H2O2 was added to start the colour reaction. The 
reaction was stopped with 1% NaN3 and read at 460nm on a Versamax microplate 
spectrophotometer (Molecular Devices, Germany). Values are expressed as units per 
gram of tissue from individual mice (see Appendix A for additional reagents for all 
experiments). 
Histological assessment of colitis. 
Distal colon sections taken 1 cm from the anus were fixed in ice cold 4% phosphate-
buffered formalin to prevent tissue autolysis. Paraffin embedded tissue was cut into 
sections and stained with haematoxylin and eosin (H&E) for inflammatory cells or 
Periodic acid-Schiff reagent (PAS) for mucus producing goblet cells. Semi-quantitative 
histopathological grading of oxazolone-induced colitis was adjusted from a previous 
study, (Iijima et al. 2004). Essentially, mice were graded on 5 criteria, 1) presence of 
mononuclear cells, 2) reduced goblet cells, 3) epithelial injury, 4) granulocyte infiltration 
and 5) oedema. Each criteria were scored from 0-3 and the total score was added 
resulting in a total additive score of between 0 (no colitis) and 15 (maximal colitis 
activity). Histology sections were processed and stained by the Department of Surgery, 
Groote Schuur Hospital. 
Isolation and restimulation of splenocytes. 
Individual or pooled spleens from oxazolone treated mice were collected in complete 
Iscoves Modified Dulbeccos Medium (IMDM) supplemented with; 10% FCS (Gibco 
Life Technologies, Paisly, UK), penicillin, streptomycin, 1mM sodium pyruvate, 50μM 
B2-ME (Sigma) and NEAA (Invitrogen). Single cell suspensions were obtained by 
pressing spleens through a 70µm cell strainer (Falcon, New Jersey, USA) and 
centrifugation at 1200rpm for 5min at 4oC in a 15ml tube. The pelleted cells were 















was repeated. Cells were resuspended in 2ml complete IMDM and stained with Trypan 
Blue (Sigma-Aldrich, Irwine, UK) to count viable cells in a haemocytometer. 
Splenocytes were diluted to 1x106 cells/ml and cultured in a 96-well plate in complete 
IMDM with anti-CD3 (clone: 145-2C11, 10μg/ml) for 48h at 37°C and 5% CO2. 
Supernatants were collected and stored at -80°C.  
Cytokine and IL-13Rα2 ELISAs. 
Sandwich ELISAs were performed to determine cytokine levels in cell supernatants and 
soluble IL-13Rα2 levels in serum. Maxisorp microtitre plates (Nunc, Reskilde, 
Denmark) were coated with purified anti-IL-4 (clone: 11B11, 2μg/ml), anti-IFN-γ (clone: 
An18KL6, 1μg/ml), anti-IL-13 (clone: 38213, 1μg/ml, BD Pharmingen, San Diego, 
USA) or anti-IL-13Rα2 (goat anti-mouse, R&D systems, U.S.A.), diluted in phosphate 
buffered saline (PBS, pH 9.5) and incubated overnight at 4°C. Plates were blocked for 3h 
at 37°C and serially diluted standards, purified recombinant IL-4, IFN-γ or IL-13 (BD 
Pharmingen) and IL-13Rα2 (R&D systems) were added. Cell supernatants or serum was 
added, diluted in ELISA dilution buffer and incubated overnight at 4°C. Biotinylated 
anti-mouse secondary antibodies for IL-4 (clone: BVD6-24G2), IFN-γ (clone: XMG1.2) 
or IL-13 (goat anti-mouse, 0.5μg/ml, BD Pharmingen) and IL-13Rα2 (goat anti-mouse, 
0.5μg/ml, R&D systems) were added for 3h at 37°C followed by HRP labelled 
streptavidin. Subsequently, plates were incubated with TMB Peroxidase Substrate (KPL, 
USA), the colour reaction stopped with 2M H2SO4 and absorption measured at 450nm. 
ELISA wash buffer was used to wash plates 4x between each step. 
Total IgE detection by ELISA. 
Total IgE levels were measured in the serum of oxazolone-treated mice (day 3 post-
challenge) by sandwich ELISA (as above). Anti-mouse IgE (clone: 84.1C) mAb was 
used for coating, purified recombinant mouse IgE (BD Pharmingen) as a standard and 
alkaline phosphotase-labelled anti-mouse IgE mAb (23G3, Southern Biotechnology, 
USA) for detection. 4-Nitrophenylphosphate (PNP, Fluka, Switzerland) dissolved at 
1mg/ml in substrate buffer was added to all samples and the absorbance measured at 
405nm.  
Flow cytometry. 
Lymphocytes and splenocytes were isolated as described above and resuspended in 















supplemented with 10% FCS and resuspended in FACS buffer for staining. Natural killer 
cells (DX5+/CD3-), T cells (DX5-/CD3+) and NK T cells (DX5+/CD3+) were quantified 
in the spleen using biotinylated mAbs for pan natural killer cell (CD49b) (clone: DX5, 
BD Pharmingen) and fluorescein isothiocyanate (FITC) anti-CD3 (clone: 145-2C11) 
mAbs. IL-13 production by NK T cells was measured by intracellular staining with 
phycoerythrin (PE) labelled anti-IL-13 antibody (clone: eBio13A, eBioscience). Spleen 
cells, 2x105 cells/well were stimulated with PMA (0.1μg/ml) and ionomycin (2μg/ml, 
both Sigma) supplemented with or without monensin (2μM, eBioscience) as a control, 
for 4h at 37°C. Intracellular expression of the decoy IL-13 receptor was measured with 
biotinylated anti-IL-13Rα2 (goat anti-mouse, R&D Systems) on various subpopulations 
of splenocytes, lymphocytes and peritoneal cells. Splenocytes were identified with anti-
CD19 (clone: 1D3), anti-CD3 (clone: 145-2C11), anti-CD4 (clone: GK1.5) or anti-
DX5/anti-CD3 and anti-CD11b/anti-GR-1 (clones: M1/70 and RB68C5) mAbs. 
Lymphocytes were identified with anti-CD19 or anti-CD4 mAbs and peritoneal cells 
were identified with anti-F4/80/anti-CD11b (clone: A3-1, Serotec, Oxford UK) or anti-
CD11b/anti-GR-1 mAbs. Biotin-labelled antibodies were detected by streptavidin-
allophycocyanin (APC). Antibodies were from BD Pharmingen (San Diego, CA) except 
where noted otherwise. Anti-FcγRII/III antibody (clone: 2.4G2) was used in order to 
block non-antigen-specific binding of immunoglobulins to the FcγII and FcγIII receptors. 
For intracellular staining, cells were stained according to the manufacturers instructions 
(eBioscience). Essentially, cells were stained for surface markers, fixed for 30min with 
fixation/permeabilization solution, permeabilized for 15min and stained with anti-IL-13 
(PE) or anti-IL-13Rα2 (Bio) antibodies. Cells were acquired using a FACSCalibur 
(Beckton-Dickinson, Ferndale, South Africa) and data were analysed with Cellquest (BD 
biosciences) or Flowjo software (Treestar). Histograms were represented as “percentage 
of maximum” which normalizes mean fluorescence per histogram based on the number 
of gated cells.   
Statistical analysis. 
Values are given as mean ± SEM, and significant differences were determined using 
unpaired two-tailed students t test or one-way ANOVA using a Bonferroni post-test 

















Oxazolone induces an UC-like Th2-mediated inflammation in BALB/c mice. 
We presensitized male BALB/c mice with 3% oxazolone 7 days before intrarectal 
challenge with 1% oxazolone solution.  As shown in Figure 1A, oxazolone induced a 
rapid onset colitis marked by weight loss peaking by day 2 and leading to death of ≥50% 
mice, with surviving BALB/c mice recovering by day 6. Macroscopic examination 3 
days post-challenge showed severe colitis limited to the distal half of the colon (Figure 
1B) with inflammation associated colon shortening compared to ethanol-only control 
BALB/c mice (Figure 1C).  
BALB/c mice treated with oxazolone showed significant signs of distress compared to 
control mice (Figure 1D). Distress was scored according to; appearance, clinical signs, 
natural and provoked behaviour. The colonic MPO activity was measured at day 3 and 
indicated significantly increased levels of neutrophil infiltration compared to ethanol 
control group (Figure 1E). Microscopic examination of the distal colon showed 
superficial inflammation characterized by epithelial cell loss, occasional patchy 
ulceration and pronounced depletion of mucous producing-goblet cells (Figure 1F). 
Furthermore, the lamina propria presented with a mixed inflammatory cell infiltrate and 
the submucosal layer had oedema with a few inflammatory cells present. The outer 
muscle layer showed little evidence of inflammation. Oxazolone-induced colitis in 
BALB/c mice was scored according to; presence of mononuclear cells, oedema, 
infiltration of granulocytes, epithelial layer disruption and loss of mucus production 
(Figure 1G). The histopathological picture of oxazolone-induced colitis highly resembles 
that seen in human UC. As 50% ethanol alone has also been shown to induce a mild 
colitis in the colon, mice treated with ethanol-only were included as controls for all 
experiments (Andrade et al. 2003). 
To characterize the systemic immune response in oxazolone colitis, cytokine production 
by spleen cells stimulated with anti-CD3 antibodies was determined 3 days after final 
challenge. IL-4 and IL-13 were increased, while no significant difference was seen in 
IFN-γ production compared with ethanol-only control mice (Figure 2A). Furthermore, 
increased levels of total IgE was detected in the serum of oxazolone-treated mice (Figure 
2B). These data show that oxazolone colitis is associated with a polarized Th2 response 

















Figure 1: Oxazolone induces an UC-like colonic inflammation in male BALB/c mice. 
Oxazolone-colitis was induced in BALB/c mice by pre-sensitization with 3% oxazolone (oxa) in 100% 
ethanol before intrarectal challenge with 1% oxa in 50% ethanol (BALB/c oxa). Control mice were 
administered ethanol only (BALB/c etoh). 
(A) Oxazolone induces rapid onset of wasting disease measured by body weight as a percentage starting 
weight (day 6 post-challenge).  
(B) Macroscopic pictures show inflammation limited to the distal half of the colon.  
(C) Inflammation is also shown by colon shortening in oxazolone-treated mice. 
(D) Mice were monitored for distress and scored according to appearance, clinical signs, natural and 
provoked behaviour (day 2 post-challenge). 
(E) Colonic myeloperoxidase (MPO) activity indicates neutrophil infiltration which was significantly 
increased in oxazolone-treated mice compared with control mice.  
(F) Histological sections from BALB/c mice treated with oxazolone or ethanol-only controls were stained 
with PAS and representative photomicrographs (x40) are shown per group. SM =submucosa, M =mucosa, 
LP =lamina propria,  infiltration of mononuclear cells, oed =oedema and U =ulceration. 
(G) Semi-quantitative histopathological assessment of colitis activity was performed based on the presence 
of mononuclear cells, oedema, epithelial damage, loss of goblet cells and granulocyte infiltration. All data 
represents mice killed 3 days post-challenge unless indicated. Data represents >3 individual experiments 
(n=4-10 mice) with mean values ± SEM and * = p <0.05, ** = p <0.01 and *** = p <0.001 vs. BALB/c 















































































































As previous studies have shown NK T cells, which secrete IL-13, to mediate the 
pathology in oxazolone colitis we measured the percentage of these cells in BALB/c 
mice (Figure 2C). We identified and quantified NK T cells in pooled spleens of 
oxazolone-treated mice by FACS analysis of surface markers for both NK and T cells. 
Representative dot plots showed a 2-fold increase in percentage NK T cells 
(DX5+/CD3+) in oxazolone-treated mice compared with controls (Figure 2C). Using 
intracellular FACS analysis of DX5+/CD3+ NK T cells, we show an increase in IL-13 
production by these cells in oxazolone-treated BALB/c mice compared to ethanol-only 
controls (Figure 2D). Together, these data demonstrate that colonic inflammation 
characteristic of oxazolone colitis in BALB/c mice is associated with a polarized Th2 

























































































Figure 2: Oxazolone induces a Th2 response in BALB/c mice 
IL-13 producing NK T cells have been shown to cause the pathology associated with oxazolone-induced 
colitis. Systemic T lymphocyte responses were assessed from spleen cells of oxazolone treated mice. 
(A) Triplicate cultures of pooled spleen cells stimulated with anti-CD3 antibody were used to measure ex 
vivo IL-4, IL-13 and IFN-γ cytokine production by ELISA. 
(B) Serum was collected from mice at day 3 post-challenge to determine total IgE levels by ELISA.  
(C) Pooled spleen cells were isolated from oxazolone treated and control mice and stained with a pan-NK 
cell marker (DX5) and CD3 for T cells. Representative dot plots show percentage NK T and CD3 cells.    
(D) Spleen cells were stimulated with PMA and ionomycin with or without Monensin (golgi blocker) and 
stained for DX5, CD3 and IL-13, to show IL-13 production by NK T cells. Data represents 3 individual 















Mice deficient in IL-13 are protected from oxazolone-induced colitis.  
The importance of IL-4 and IL-13 cytokines in oxazolone colitis has been shown by 
previous studies in SJL/J and C57BL/10. To determine whether IL-4 and IL-13 play such 
a crucial role in BALB/c mice, we treated mice deficient for both IL-4 and IL-13 (IL-
4/IL-13-/-) with oxazolone and compared the disease outcome to wild type controls.  As 
shown in Figure 3A, IL-4/IL-13-/- mice were protected from weight loss as they rapidly 
regained their initial body weight and showed no macroscopic signs of inflammation 
(Figure 3B), with the colon length remaining significantly longer than oxazolone-treated 
BALB/c mice (Figure 3D). Distress was scored as mentioned above and MPO activity 
was measured 3 days after challenge with oxazolone and showed IL-4/IL-13-/- mice to 
have symptoms indistinguishable from ethanol control mice (Figure 3C and 3E). In 
addition, IL-4/IL-13-/- mice presented with significantly less histopathology when 
compared with oxazolone treated BALB/c mice (Figure 3F and 3G). As expected, in 
vitro stimulated splenocytes from IL-4/IL-13-/- mice did not produce IL-4 or IL-13 
(Figure 4A). Furthermore, numbers of T cells and NK T cells were reduced (Figure 4B).  
These data confirms the importance of IL-4 and/or IL-13 signalling in mediating 
oxazolone-induced colitis in BALB/c mice. To determine the individual roles of IL-4 and 
IL-13 we treated both IL-4-/- and IL-13-/- BALB/c mice with oxazolone and compared the 
disease onset with wild type mice. Table 1 and Table 2 summarize our data, which 
suggests that mice deficient in IL-4 production were not completely protected from 
oxazolone-induced colitis. This was shown by a significant increase in weight loss, 
















Figure 3: IL-4/IL-13 mediates oxazolone-induced colitis in BALB/c mice. 
Mice deficient in both IL-4 and IL-13 (IL-4/IL-13-/-) were protected from the rapid onset of colitis induced 
by oxazolone shown by; 
(A) Reduced loss of body weight as percentage starting weight compared with BALB/c oxa mice (day 6).  
(B) Normal colon appearance in macroscopic pictures.  
(C) Significantly less distress, according to severity of symptoms with a maximum score of 16 (day 2). 
(D) Normal colon length, indicating reduced inflammation.  
(E) Reduced colonic MPO activity comparable to control mice.  
(F) Significantly reduced colitis score based on a semi-quantitative histopathological assessment.  
(G) Reduced or no oxazolone-induced inflammation shown in PAS-stained sections of the distal colon, 
while BALB/c mice show oedema (oed), reduced mucous production and inflammatory infiltrates ( ). 
SM =submucosa and M =mucosa. All data represents mice killed 3 days post-challenge unless indicated. 
Data represents 3 individual experiments (n=6-8 mice) with mean values ± SEM and * = p <0.05, ** = p 
<0.01 and *** = p <0.001 vs. BALB/c etoh controls and # = p <0.05 and ## = p <0.01 BALB/c oxa vs. IL-















































































































































































































Figure 4: Abrogated Th2 response to oxazolone in IL-4/IL-13 deficient mice. 
Systemic T lymphocyte responses were assessed from spleen cells of oxazolone treated IL-4/IL-13-/- mice 
and compared to oxazolone treated or control wild type BALB/c mice. 
(A) Systemic cytokine production from splenocytes were analysed by ELISA showing expected abrogation 
of IL-4 and IL-13 and no effect on IFN-γ levels. This confirms the functional deletion of IL-4/IL-13.  
(B) Pooled spleen cells isolated from oxazolone treated and control mice were stained with a pan-NK cell 
marker (DX5) and CD3 for T cells.  
Data represents 2 individual experiments (n =6-8), with mean ± SEM and ** = p <0.01 and *** = p <0.001 

















In contrast, mice deficient in IL-13 production were significantly protected from 
oxazolone-induced colitis. This was shown by a significant decrease in weight loss, 
distress and colitis with abrogated IL-13 production compared to oxazolone-treated 
BALB/c mice (Table 1 and Table 2). Furthermore, we showed that mice over expressing 
IL-13 (IL-13 trans) presented with a more severe oxazolone colitis than BALB/c mice. 
Data represented in Table 1 and Table 2 show significantly increased weight loss, 
distress and colitis with high levels of IL-13 production in IL-13 trans compared with 
BALB/c oxazolone-treated mice. These data confirm a crucial role for IL-13 in UC as 
recently shown by (Weigmann et al. 2008).  
 
Table 1: Disease activity in oxazolone treated gene-deficient or transgenic BALB/c mice. 
 
Groups Body weight a Survivalb Distress Scorec Colon length (cm) 
BALB/c etoh 98.19 ± 1.6 83.33 ± 15.2 3.33 ± 0.2 8.23 ± 0.5 
BALB/c oxa 91.66 ± 1.8 * 57.14 ± 18.7 * 9.38 ± 0.9 *** 6.81 ± 0.4 * 
IL-4-/- 89.85 ± 1.4 ** (62.50 ± 17.1) 9.34 ± 1.2 ** 7.84 ± 0.6 
IL-13-/- 98.74 ± 1.5 # (87.50 ± 11.7) 5.50 ± 0.5 # 9.53 ± 0.6 
IL-13 trans 88.50 ± 1.2 # ----------------- 12.33 ± 1.2 ## 6.5 ± 0.6 ** 
IL-4Rα/IL-4-/- 87.21 ± 2.2 ** 27.27 ± 13.4 * 9.00 ± 1.4 * 7.47 ± 0.1 * 
a Body weight is shown as percentage starting weight 2 days post-challenge. 
b Percentage survival shown for 7 days post-challenge. Brackets are from 3 day survival curves only. 
c Distress is scored according to appearance, clinical signs, natural and provoked behaviour. 
* = p <0.05, ** = p <0.01 and *** = p <0.001 vs BALB/c etoh control. 
# = p <0.05 and ## = p <0.01 BALB/c oxa vs. genetically modified mice. 
 
 
Table 2: Inflammatory response to oxazolone in gene-deficient or transgenic BALB/c mice. 
 
Groups Colitis score a IL-4 (ng/ml) IL-13 (ng/ml) IFN-γ (ng/ml) 
BALB/c etoh 2.78 ± 0.5 0.013 ± 0.005 0.24 ± 0.004 11.26 ± 0.2 
BALB/c oxa 8.33 ± 0.8 *** 0.076 ± 0.01 ** 0.88 ± 0.01 *** 43.08 ± 8.3 * 
IL-4-/- 6.78 ± 1.3 * ND 0.51 ± 0.004 ** 29.60 ± 8.2 
IL-13-/- 5.50 ± 0.6 # 0.012 ± 0.06 ## ND 68.44 ± 14.1 
IL-13 trans 12.00 ± 0.5  ##  0.063 ± 0.005 3.24 ± 0.04 ### 43.28 ± 1.5 * 
IL-4Rα/IL-4-/- 9.57 ± 0.5 *** ND 0.28 ± 0.004 ### 34.10 ± 0.2 * 
a Semi-quantitative histopathological assessment of colitis activity was performed based on the presence of 
mononuclear cells, oedema, epithelial damage, loss of goblet cells and granulocyte infiltration. 
* = p <0.05, ** = p <0.01 and *** = p <0.001 vs BALB/c etoh control. 

















Deletion of the common receptor for IL-4 and IL-13, IL-4Rα exacerbates oxazolone-
induced colitis. 
IL-4 and IL-13 both signal via the IL-4Rα. Considering our previous results (supported 
by Weigmann et. al. 2008) which demonstrate the importance of IL-13 in mediating 
oxazolone-colitis, we expected to inhibit disease development in BALB/c mice lacking 
this receptor on all cells (IL-4Rα-/-mice). Interestingly, IL-4Rα-deficient mice developed 
more severe oxazolone colitis than BALB/c mice. As shown in Figure 5A, IL-4Rα-/- mice 
weighed significantly less than both oxazolone or ethanol-treated BALB/c mice, with a 
mortality rate > 25% (Figure 5B). In some experiments oxazolone-treatment even 
resulted in total loss of all IL-4Rα-/- mice, either due to death or killing of mice that had 
lost ≥20% body weight. Macroscopic examination 3 days post-challenge showed severe 
colitis limited to the distal half of the colon with inflammation associated colon 
shortening compared with oxazolone-treated BALB/c mice (Figure 5C). IL-4Rα-/- mice 
also showed significant signs of distress (Figure 5D) and MPO levels comparable to 
BALB/c mice (Figure 5E). Microscopic examination of the distal colon showed 
superficial inflammation characterized by epithelial cell loss, patchy ulceration and 
pronounced depletion of mucous producing-goblet cells. The oxazolone-induced colitis, 
scored according to; presence of mononuclear cells, oedema, infiltration of granulocytes, 
epithelial layer disruption and loss of mucus production was significantly increased in 
IL-4Rα-/- mice compared to oxazolone-treated BALB/c mice (Figure 5F and 5G).  
IL-4Rα-/- mice have an impaired systemic Th2 response in oxazolone colitis with 
decreased IL-4, IL-13 and no total IgE production (Figure 6A and 6B). Interestingly, 
these mice develop severe colitis despite impaired systemic IL-13 production. The 
percentage of NK T and CD3+ cells remains elevated, comparable to oxazolone-treated 
BALB/c mice (Figure 6C). These data demonstrate that mice deficient in the common 
receptor for IL-4 and IL-13 signalling, IL-4Rα develop severe oxazolone-induced colitis. 
This result was unexpected as it has been shown previously that both ligands of IL-4Rα 
















Figure 5: Deletion of IL-4Rα exacerbates oxazolone-induced colitis. 
Both IL-4 and IL-13 signal via the IL-4Rα and deleting this receptor is expected to protect mice from 
oxazolone-induced colitis. However, IL-4Rα-/- mice show severe disease onset compared to BALB/c mice 
in response to oxazolone. This is shown by: 
(A) Significantly increased weight loss peaking at 5 days post-challenge (day 6). (B) Higher mortality with 
complete loss of mice in some experiments (day 6). (C) Significantly more distress, scored according to 
severity of symptoms (day 2). (D) Severe macroscopic colon inflammation with reduced colon length. (E) 
MPO activity comparable to oxazolone treated BALB/c mice. (F) Increased colitis score based on a semi-
quantitative histopathological assessment. (G) Severe inflammation shown in PAS-stained sections of the 
distal colon, with oedema (oed), reduced mucous production and inflammatory infiltrates ( ). All data 
represents mice killed 3 days post-challenge unless indicated. Data represents 3 individual experiments 
(n=4-10 mice) with mean values ± SEM and * = p <0.05 and ** = p <0.01 vs. BALB/c etoh control and # = 
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Figure 6: IL-4Rα-deficient mice have exacerbated colitis despite an impaired Th2 response. 
Systemic T lymphocyte responses were assessed from spleen cells of oxazolone treated IL-4Rα-/- mice and 
compared to oxazolone treated or control wild type BALB/c mice. 
(A) Despite the severity of disease onset, systemic cytokine production from the spleen analyzed by 
ELISA showed significantly reduced levels of IL-13 production.  
(B) Serum IgE levels were measured by ELISA. 
(C) Pooled spleen cells isolated from oxazolone treated and control mice were stained with a pan-NK cell 
marker (DX5) and CD3 for T cells. Exacerbated disease in IL-4Rα-/- mice corresponded with increased 
numbers of NK T cells. Data represents 2 individual experiments (n =4-10), with mean ± SEM and * = p 
<0.05 ** = p <0.01 vs. BALB/c etoh control and # = p <0.05 ## = p <0.01 and ### = p <0.001 BALB/c oxa 















IL-13 causes colitis in IL-4Rα-deficient mice. 
After confirming the importance of IL-13 we wanted to determine if IL-13 causes 
oxazolone-induced colitis in IL-4Rα-deficient mice, possibly by signalling through 
another receptor. IL-4Rα-/- mice were crossed with IL-13-/- mice generating IL-4Rα/IL-
13-double deficient BALB/c mice. Our data showed the protection of IL-4Rα/IL-13-/- 
mice from oxazolone-induced colitis with weight loss comparable to ethanol-only 
control mice (Figure 7A). Furthermore, IL-4Rα/IL-13-/- mice had a lower mortality rate 
(Figure 7B) and macroscopic colon appearance similar to ethanol-only control mice 
(Figure 7C). As IL-4Rα/IL-13-/- mice were smaller at 6-8 weeks old, colon length was 
measured relevant to starting weight before oxazolone treatment and was comparable to 
ethanol-only control BALB/c mice (Figure 7C). Although IL-4Rα/IL-13-/- mice were 
distressed compared to ethanol-only controls, they were significantly less distressed than 
oxazolone-treated IL-4Rα-/- mice (Figure 7D).  
Systemic T lymphocyte responses from stimulated spleen cells showed IL-4Rα/IL-13-/- 
mice maintaining high levels of IL-4 production comparable to oxazolone-treated IL-
4Rα-/- mice and no detectable levels of IL-13, confirming the efficiency of IL-13 deletion 
(Figure 8A). IFN-γ production was not significantly different to ethanol-only control 
mice. Microscopic examination of the distal colon showed no significant superficial 
inflammation, no ulceration and very little depletion of mucous producing-goblet cells in 
IL-4Rα/IL-13-/- mice (Figure 8B). Furthermore, the lamina propria presented with very 
mild inflammatory cell infiltrate and only slight oedema of the submucosa in some mice. 
Scoring of colitis showed no significant difference between IL-4Rα/IL-13-/- and ethanol 
control mice but significantly reduced colitis compared with oxazolone-treated IL-4Rα-/- 
mice (Figure 8C). Lastly, neutrophil activity was significantly reduced in protected IL-
4Rα/IL-13-/- mice compared with oxazolone-treated IL-4Rα-/- mice (Figure 8D). The 
protection seen was specific to IL-13 as mice deficient in both IL-4Rα and IL-4 (IL-
4Rα/IL-4-/-) were not protected from oxazolone colitis (data shown in Table 1 and 2). IL-
4-Rα/IL-4-/- mice showed weight loss, mortality, distress and colon inflammation and 
shortening comparable to wild type BALB/c mice treated with oxazolone. Furthermore, 
these mice had no detectable IL-4 with significantly reduced levels of IL-13 production. 
Together these data confirm that IL-13 is responsible for mediating pathology in 


















































































































































Figure 7: IL-13 causes colitis in IL-4Rα-deficient mice. 
To determine if IL-13 signalling independently of the IL-4Rα would cause oxazolone-induced colitis, mice 
deficient in both the IL-4Rα and IL-13 (IL-4Rα/IL-13-/-) were treated with oxazolone. These mice were 
significantly protected from disease onset compared with IL-4Rα-/- oxazolone treated mice. The double 
knockout mice showed; 
(A) Reduced weight loss comparable to ethanol-only control BALB/c mice (day 6), (B) decreased 
mortality (day 6), (C) normal colon appearance in macroscopic pictures and normal length relative to 
starting weight, and (D) significantly less distress (day 2). All data represents mice killed 3 days post-
challenge unless indicated. Data represents 2 individual experiments (n=4-8) with mean values ± SEM and 
* = p <0.05, ** = p <0.01 and *** = p <0.001 vs. BALB/c etoh control and # = p <0.05, IL-4Rα-/- oxa vs. 































































































































Figure 8: IL-13 deficiency protects IL-4Rα-/- mice from colitis. 
Systemic T lymphocyte responses were assessed from spleen cells of oxazolone treated IL-4Rα/IL-13-/- 
mice and compared to oxazolone treated IL-4Rα-/- mice. 
(A) IL-4Rα/IL-13-/- mice were protected from disease corresponding to abrogated levels of IL-13. 
Systemic cytokine production from the spleen was analysed by ELISA. 
(B) Histological sections were stained with PAS and representative photomicrographs (x40) shown. SM 
=submucosa, M =mucosa,  = presence of mononuclear cells and oed = oedema. 
(C) Semi-quantitative histopathological assessment of colitis activity was performed based on the presence 
of mononuclear cells, oedema, epithelial damage, loss of goblet cells and granulocyte infiltration.  
(D) MPO activity in oxazolone-treated IL-4Rα/IL-13-/- mice was significantly reduced compared to IL-
4Rα-/- mice. Data represents 2 individual experiments (n=4-8) with mean values ± SEM and * = p <0.05, 
** = p <0.01 and *** = p <0.001 vs. BALB/c etoh controls and # = p <0.05 and ## = p <0.01, IL-4Rα-/- oxa 















A role for IL-13 signalling via IL-13Rα2 in oxazolone colitis. 
IL-13Rα2 transcripts have been found in the spleen, liver, lung, thymus and brain (Guo 
et al. 1997; Donaldson et al. 1998) and the receptor has been described predominantly as 
an intracellular molecule in monocytes and respiratory epithelial cells (Daines and 
Hershey 2002). We used FACS analysis to determine if the IL-13Rα2 was expressed in 
spleen, peritoneal and lymph node cell populations and if oxazolone-induced colitis had 
any effect on expression in these cells. Spleen B cells, T cell subpopulations (CD4+, 
CD3+ and NK T cells) and natural killer cells showed expression of IL-13Rα2 which was 
unaffected by oxazolone colitis (Figure 9A). Similarly, peritoneal macrophages and T 
and B cells from the lymph node showed unaffected IL-13Rα2 expression. Interestingly, 
spleen and peritoneal GR-1high/CD11b+ cells indentified as neutrophils (by size and 
granularity), demonstrated reduced expression of IL-13Rα2 in oxazolone-treated 
BALB/c mice represented by geometric mean expression (Figure 9A). Pooled spleen and 
peritoneal cells from individual mice were analysed by FACS  and the geometric mean 
expression of IL-13Rα2 was 3.42 ± 0.08 for BALB/c ethanol-isotype control, 8.92 ± 0.58 
BALB/c ethanol-IL-13Rα2 and 6.89 ± 0.66 BALB/c oxazolone-IL-13Rα2  (n=4). A 
significant reduction (p <0.05) was seen in IL-13Rα2 expression on peritoneal 
neutrophils of BALB/c mice treated with oxazolone compared with ethanol-only control 
cells.  
The soluble form of IL-13Rα2 has previously been found to be increased in serum of 
Schistosoma mansoni infected mice (Mentink-Kane et al. 2004). Therefore, we 
quantified soluble IL-13Rα2 levels in serum of oxazolone-treated gene deficient mice.  
Soluble IL-13Rα2 was detected in the serum of control BALB/c mice treated with 
ethanol-only. This level was significantly reduced in mouse groups that presented with 
colitis such as, oxazolone-treated BALB/c, IL-4Rα-/- and IL-4Rα/IL-4-/- mice. In contrast, 
IL-4Rα/IL-13-/- mice protected from colitis and lacking IL-13 production, showed no 
significant change in soluble IL-13Rα2 levels compared with ethanol-only control mice 
(Figure 9B).  
Together these data demonstrate that expression of the IL-13Rα2 is not limited to 
specific cell types but rather appears to be widespread and that oxazolone colitis down 













































































































Figure 9: IL-13Rα2 expression and secretion in oxazolone-induced colitis 
(A) Spleen cells were CD4+ or CD3+ (T cells), CD19+ (B cells), DX5+/CD3+ (NK T cells), DX5+/CD3- 
(natural killer cells) or GR-1hi/CD11b+ (neutrophils). Peritoneal cells were F4/80+/CD11b+ (macrophages) 
and GR-1hi/CD11b+ (neutrophils). Lymph node cells were CD4+ or CD19+ for T and B cells. Groups were, 
BALB/c ethanol-control-isotype (greyscale), BALB/c ethanol-control-IL-13Rα2 (dotted line) and BALB/c 
oxa-IL-13Rα2 (black solid line). 
(B) Oxazolone colitis was associated with decreased levels of soluble IL-13Rα2 in the serum of 
susceptible mouse strains. Serum was taken from mice and IL-13Rα2 measured by ELISA. Data represents 
2 individual experiments of mice killed on day 3 post-challenge (n=4-8).  Mean values are ± SEM and * = 

















We show that IL-13 can induce the pathology associated with oxazolone colitis  
independently of IL-4Rα. Oxazolone colitis is a form of experimental colitis mediated by 
type-2 responses which resemble human ulcerative colitis. Colitis was induced in male 
BALB/c mice by intrarectal administration of oxazolone subsequent to skin sensitization. 
Disease was characterized by rapid onset inflammation peaking at day 2 post-challenge 
and leading to wasting disease and death or complete recovery. Histological assessment 
demonstrated a superficial colitis with ulceration and an inflammatory infiltrate of 
lymphocytes and granulocytes. Previous studies show that IL-4 is produced in the initial 
stages of colitis but is rapidly superceded by IL-13 production and that blocking either 
one of these cytokines protects C57BL/10 or SJL/J mice from developing disease 
(Boirivant et al. 1998; Heller et al. 2002).  
The susceptibility of mice to oxazolone-induced colitis is dependent on the strain. Pre-
sensitization leads to a prolonged colitis, opposed to severely acute disease resulting in 
sudden death or quick recovery. The oxazolone model was first described in a highly 
susceptible SJL/J mouse strain (Boirivant et al. 1998) and then established in C57 
background strains for the benefit of using genetically manipulated mice (Heller et al. 
2002; Nieuwenhuis et al. 2002). C57/BL6 mice have a tendency towards Th1 immune 
responses (Charles et al. 1999) and therefore require pre-sensitization with oxazolone to 
induce UC. BALB/c mice are widely recognised as a strain that is predisposed to Th2 
immune responses and a number of genetically modified mice are currently available on 
this background. Oxazolone colitis has been successfully induced in BALB/c mice and 
the tissue damage (although transient) reflects that of human UC (Kojima et al. 2004). 
We adjusted previous protocols and pre-sensitized BALB/c mice to obtain a reliable 
model of colitis resembling human ulcerative colitis.  By using BALB/c mice lacking or 
over expressing genes crucial in mediating Th2 responses, such as IL-4, IL-13 and IL-
4Rα we investigated a role for these genes in the pathology of oxazolone colitis. 
The importance of IL-4 and IL-13 signalling has been highlighted in previous oxazolone 
colitis studies and confirmed by our data using IL-4 and IL-13 deficient and IL-13 
transgenic mice. Although blocking IL-4 has previously been shown to protect SJL/J 
mice from developing oxazolone colitis (Boirivant et al. 1998), genetic variability in 
mice could account for differences in the role of IL-4 in BALB/c mice. Unexpectedly, 















oxazolone. This suggests that IL-4Rα plays a regulatory role in colitis and that although 
IL-4 and IL-13 mediate colitis, the receptor through which they commonly signal is also 
essential to counterbalance an exaggerated response. The inflammation seen in IL-4Rα-/- 
mice resembled oxazolone treated BALB/c mice with a higher severity. The disease was 
relatively limited to the distal colon with the microscopic picture showing increased 
ulceration and epithelial damage. These symptoms were limited to the colon and 
remained comparable to ulcerative colitis and not a shift towards a type-1 mediated 
colitis. Furthermore, removing IL-13 but not IL-4 signalling from IL-4Rα-deficient mice, 
significantly protected them compared with wild type BALB/c mice.  
Our data suggests that IL-13 has another signalling pathway apart from IL-4Rα to 
mediate oxazolone-induced colitis. Previous studies have shown that the expression of 
IL-13Rα1 and IL-4Rα together was sufficient to render cells responsive to IL-13 (Miloux 
et al. 1997; Hershey 2003). The expression of IL-13Rα2 in vitro resulted in high-affinity 
binding of IL-13 but was insufficient to render cells responsive to IL-13 (Donaldson et 
al. 1998). Furthermore, IL-13Rα2 was found in a soluble form in vivo (Zhang et al. 
1997) and it’s over expression was shown to diminish IL-13 signalling (Kawakami et al. 
2001; Daines and Hershey 2002). Together these studies led to speculation that the IL-
13Rα2 was a decoy receptor relaying no signal. Recent studies have shown that IL-13 
does indeed signal through the IL-13Rα2 by activating AP-1 to induce TGF-β secretion 
(Fichtner-Feigl et al. 2006). Therefore the IL-13Rα2 is a good candidate for IL-13 
signalling to mediate oxazolone-induced colitis. 
The precise mechanism of IL-13 signalling via IL-13Rα2 is unclear. However, 
macrophages have been shown to produce increased levels of TGF-β in response to IL-
13Rα2 signalling. Increased levels of TGF-β in mice treated with oxazolone protect mice 
from colitis (Fichtner-Feigl et al. 2006). It has also been suggested that because the 
concentration of TGF-β is higher in the proximal colon, oxazolone colitis is limited to 
the distal colon (Boirivant et al. 1998). Considering this data, IL-13 signalling via the IL-
13Rα2 should promote protection from disease by increasing TGF-β. Furthermore, IL-
13Rα2 up regulation has been shown to be dependent on signalling via TNFR1 and IL-
4Rα (Fichtner-Feigl et al. 2006); however we show that IL-13 manages to mediate 
disease in IL-4Rα-/- mice. Previous studies have shown IL-13Rα2 to prolong host 
survival to S. mansoni infection by suppressing chronic type-2-mediated inflammation. 















type-2-mediated disease (Mentink-Kane et al. 2004). Our data shows that reduced serum 
levels of IL-13Rα2 are associated with disease pathology in oxazolone colitis.  
We found IL-13Rα2 expression in many cell types including; T and B lymphocytes, 
natural killer cells, macrophages and neutrophils. Oxazolone-induced colitis only 
affected the level of expression of IL-13Rα2 in neutrophils, in which it was reduced. 
This data suggests a complex role for IL-13 signalling via the IL-13Rα2 in disease. In 
summary, our results suggest that IL-13/IL-13Rα2 signalling causes disease in 
oxazolone-induced colitis. Together this data can define a role for IL-13 or IL-13Rα2 
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Oxazolone-induced colitis is a T helper cell type 2 (Th2)-mediated disease which is 
analogous to human ulcerative colitis (UC). Th2 cytokines interleukin (IL)-4 and IL-13 
both signal through a common IL-4 receptor α chain (IL-4Rα) and are associated with 
the onset of UC. However, the cell-specific requirements for IL-4Rα are unclear. In this 
study we characterized a novel BALB/c mouse model lacking IL-4Rα expression 
specifically on B cells (mb1creIL-4Rα-/lox) to investigate the possible role of IL-4Rα 
responsive B cells during oxazolone colitis. Efficient deletion was confirmed by loss of 
IL-4Rα expression on CD19+ and B220+ B cells and impaired IL-4/IL-13 driven antibody 
response to ovalbumin. In contrast to hemizygous littermate control mice (IL-4Rα-/lox), 
which developed severe colitis in response to oxazolone, mb1creIL-4Rα-/lox mice were 
protected from disease despite increased levels of IL-4 and IL-13. Protection correlated 
with impaired IgE and IgG1 antibody responses.  
Therefore we examined the effect of anti-IgE and anti-FcRγII/III antibodies on BALB/c 
mice treated with oxazolone. Blocking IgE significantly protected BALB/c mice from 
the onset of colitis as shown by reduced weight loss, colon shortening, distal colon 
pathology and death, whereas anti-FcRγII/III treatment had no effect. Furthermore, anti-
IgE antibody treatment and protection against oxazolone-induced colitis was associated 
with significantly reduced mast cell numbers in the distal colon of protected mice. In 
conclusion, our studies demonstrate that IL-4Rα expression on B cells is crucial for 
















Early studies have shown an increase in IgG1 antibody production in ulcerative colitis 
(UC) patients compared to patients with Crohn's disease (CD) (Kett et al. 1987). 
Conversely, the proportions of IgG2 antibodies were significantly higher in CD patients 
than in UC. Furthermore, elevated levels of IgE have also been shown in UC patients 
(Ceyhan et al. 2003). Differences in the type of antibody response between the two types 
of inflammatory bowel disease (IBD) suggest dissimilar mucosal exposure to antigenic 
stimuli with type 2 antibodies playing a dominant role in UC. Considering the 
heterogeneity of UC, many aspects of the initial events leading to B cell mediated 
immunopathology and the mechanisms involving IL-4, IL-13 and type 2 antibody 
responses remains undefined. 
Distinguishing different B cell subpopulations by surface expression of activation 
markers, identified a unique population of activated CD19+ B lymphocytes in UC when 
compared with Crohn’s disease (CD) or normal patients (Yacyshyn 1993). This data 
suggests differing roles for B cells in UC and CD. Furthermore, a striking feature of UC 
is the substantial and uniform occurrence of IgG producing plasma cells along diseased 
mucosa (Kett et al. 1987). Antibody-mediated hypersensitivity is suggested to be a 
principal mediator of tissue damage in UC, with IgG+ plasma cells being of primary 
pathogenic significance (MacDonald and Monteleone 2006). Although there is a 
predominant role for IgG antibodies in UC, IgE is known to play an important role in 
inflammatory reactions. Furthermore, IBD patients particularly with UC, show prevalent 
allergic symptoms and high IgE levels (Ceyhan et al. 2003). The importance of IgE in 
colitis is further supported by a study using the dextran sulphate sodium (DSS)-induced 
mouse model of colitis, in which blocking IgE suppressed colitis (Kang et al. 2006). 
These studies suggest that IgE-dependent mechanisms may be involved in the 
pathogenesis of UC. 
IgE binds to the FcεRI on the surface of mast cells (Akdis 2006), the second exposure to 
antigen leads to cross-linking of bound IgE resulting in mast cell degranulation releasing 
potent inflammatory mediators (Sampson 1999; van Drunen and Fokkens 2006). 
Intestinal mast cell numbers have been reported to be either increased or decreased in 
patients with ulcerative colitis. These discrepancies have been suggested to be due to 
differences in methods of preparing tissue sections or due to degranulation of activated 















mediators, such as tryptase and TNF-α, suggest mast cell activation by IgE cross-linking 
in UC (Bischoff et al. 1996; Raithel et al. 2001). IL-4 and possibly IL-13 induce IgE 
isotype switching in mouse B cells via the IL-4Rα (Finkelman et al. 1988; Bonnefoy et 
al. 1996; Lai and Mosmann 1999; Brombacher 2000). Deleting IL-4Rα specifically from 
B cells would determine a role for IL-4/IL-13 responsive B cells in oxazolone-induced 
colitis. 
IL-4 and IL-13 are closely related cytokines with pleiotropic immune functions mediated 
through a shared receptor subunit, IL-4Rα (Brombacher 2000). The IL-4Rα chain, in 
association with the gamma common (γc) chain, binds IL-4 with high affinity. It also 
functions as a component of the IL-13 receptor by binding with IL-13Rα1 (Nelms et al. 
1999). Both cytokines are involved in mechanisms promoting UC (Boirivant et al. 1998; 
Kojima et al. 2004; Wang et al. 2004) and allergic pathology (Grunig et al. 1998; Wills-
Karp et al. 1998). Therefore, IL-4Rα mediates tissue damage or confers immunity 
depending on cell type-specific expression or the type of stimulus (Brombacher 2000).  
The cellular contributions of IL-4Rα in inflammatory disease can be dissected by using 
mice deficient in IL-4Rα expression on specific cell types. In this study, we addressed 
the role of B cell IL-4Rα expression in UC. This was achieved by generating a B cell-
specific IL-4Rα-deficient mouse (mb1creIL-4Rα-/lox). Our results demonstrate the 
successful generation of transgene-bearing mb1creIL-4Rα-/lox BALB/c mice that have 
effective impairment of IL-4Rα specifically on B cells. We used a mouse model of 
allergic asthma to functionally characterize mb1creIL-4Rα-/lox mice and showed that mice 
sensitized with ovalbumin lack type 2 antibody responses but remain susceptible to 
ovalbumin-induced allergic asthma. This data suggests signalling via the IL-4Rα on B 
cells is required for type 2 antibody production. Similarly, mb1creIL-4Rα-/lox mice treated 
with oxazolone to induce a Th2-mediated ulcerative colitis also had disrupted type 2 
antibody responses. However, these mice were significantly protected from colitis 
suggesting the involvement of IgE or IgG1 in ulcerative colitis. Subsequently we showed 
that, BALB/c mice treated with anti-IgE but not anti-FcγRII/III antibodies were 
protected from oxazolone-induced colitis with a reduction in mast cell numbers. 
Therefore, IgE production by IL-4 responsive B cells induces ulcerative colitis in 















MATERIALS AND METHODS 
Generation and genotyping of mb1creIL-4Rα-/loxBALB/c mice.  
Transgenic mb1cre mice (Hobeika et al. 2006) were first backcrossed to BALB/c for nine 
generations and then intercrossed with IL-4Rα-deficient (IL-4Rα-/-) and IL-4Rαlox/lox) 
mice to generate mb1creIL-4Rα-/lox BALB/c mice. Transgene negative littermates (IL-
4Rα-/lox) were used as controls in all experiments. Specific PCR primer pairs were used 
to confirm the genotype of mb1creIL-4Rα-/lox mice. IL-4Rα: 5'-TGACC-
TACAAGGAACCCAGGC-3' and 5'-CTCGGCGCACTGACCCATCT-3'; deletion: 5'-
GGCTGCTGACCTGGAATAACC-3' and 5'-CCTTTGAGAACTGCGGGCT-3'; LoxP: 
5'-CCCTTCCTGGCCCTGAATTT-3' and 5'-GTTTCCTCCTACCGCTGATT-3' hCre: 
5'-ACCTCTGATGAAGTCAGGAAGAAC-3' and 5'-GGAGATGTCCTTCACTCTG-
ATTCT-3'. PCR conditions were as follows: 94°C/1min, 94°C/30sec, 55°-60°C/20sec 
and 72°C/1min for 40 cycles on a MJ thermocycler (Biozym, Hessissch Olderdorf, 
Germany). Routine genotyping was performed by Wendy Green and Rayaana Fredericks 
in the Division of Immunology. Male mice on a BALB/c background were used for 
oxazolone experiments, while sex matched mice were used for characterization and 
allergy experiments. Mice (aged 6-10 weeks) were bred and housed in specific pathogen-
free conditions at the University of Cape Town, South Africa. All experiments were 
approved by the University’s Animal Ethics Committee. 
Efficiency of IL-4Rα deletion by Real-Time PCR. 
Genomic DNA was prepared from CD3+CD19- and CD3-CD19+ sorted lymph node cells 
(>99% purity) from mb1creIL-4Rα-/lox, IL-4Rα-/lox and IL-4Rα-/- mice using a 
FACsvantage flow cytometer (BD biosciences, Ferndale, South Africa). A standard 
curve was prepared of serial 10-fold dilutions from DNA product using primers specific 
for IL-4Rα exon 5 (control) and exon 8 (deleted by hCre expression). Primers: exon 5 
forward: 5'-AACCTGGGAAGTTGTG-3' and reverse: 5'-CACAGTTCCATCTGGTAT -
3'; exon 8 forward: 5'-GTACAGCGCACATTGTTTTT-3' and reverse 5'-CTCGGCG- 
CACTGACCCATCT-3'. (See Appendix A for solutions and supplementary methods) 
Flow Cytometry. 
IL-4Rα surface expression was detected on spleen or lymph node cells by phycoerythrin 
(PE) or biotinylated anti-CD124 (IL-4Rα, clone: M-1). Cell subpopulations were 















CD19 (clone: 1D3), B220 (clone: RA3-6B2), CD3 (clone: 145-2C11), CD4 (clone: 
GK1.5), CD8 (clone: 53.6.72), pan-natural killer (clone: DX5), CD11b (clone: M1/70) 
and F4/80 (clone: A3-1, Serotec, Oxford UK). Surface expression of the low affinity IgE 
receptor, CD23 (clone: B3B4) was analysed on CD3+ and CD19+ cells from spleen, 
lymph node and lung suspensions. Biotin-labelled antibodies were detected by 
streptavidin-allophycocyanin (APC) and dead cells were excluded from analysis by 7-
AAD staining (Sigma). Antibodies were from BD Pharmingen (San Diego, CA) except 
where noted otherwise. The anti-FcR (clone: 2.4G2) was used in order to block non-
antigen-specific binding of immunoglobulins to the FcγII and FcγIII receptors. Cells 
were acquired using a FACSCalibur (Beckton-Dickinson, Ferndale, South Africa) and 
data were analysed with Cellquest (BD biosciences) or Flowjo software (Treestar). 
T cell proliferation. 
Lymph node CD4+ T cells were positively selected using anti-CD4 coupled to 
microbeads (MACS, Miltenyi Biotec) to a purity of >90% as confirmed by FACS. Single 
cell suspensions prepared from lymph nodes were incubated with anti-CD4 microbeads 
and passed through an LS separation column (max 108 cells). The magnetically labelled 
CD4+ cells were retained in the column while unlabeled cells ran through. After removal 
from the magnetic field, CD4+ cells were eluted and viable cells counted using Trypan 
Blue exclusion (Sigma). Triplicates of 5x105 cells/ml were stimulated with serial 
dilutions of IL-4 or IL-2 (BD Pharmingen) in complete Iscoves Modified Dulbeccos 
Medium (IMDM) supplemented with 10% FCS (Gibco Life Technologies, Paisly, UK), 
penicillin, streptomycin, 1mM sodium pyruvate, 50 μM B2-ME (Sigma) and NEAA 
(Invitrogen). After 48h of incubation at 37°C and 5% CO2, cells were pulsed with 1μCi 
[3H] thymidine (AEC Amersham, Uppsala, Sweden) and incubated for a further 18h. 
[3H] incorporation was measured in a liquid scintillation counter and results were 
expressed as counts per minute (cpm). 
In vitro Th2 differentiation. 
Positively selected CD4+ T cells, enriched to a purity of >90% (described above) were 
used for in vitro Th1/Th2 differentiation as previously described (Mohrs et al. 2000; 
Herbert et al. 2004; Radwanska et al. 2007; Dewals et al. 2009). Briefly, 1x106 cells/ml 
were cultured on anti-CD3 (clone: 145-2C11, 10μg/ml) and anti-CD28 (clone: 37.51, 















(50ng/ml) and neutralising antibody against IL-4 (clone: 11B11, 10μg/ml) or IFN-γ 
(clone: An18KL6, 50μg/ml). After 72h, the cells were washed and supplemented with 
new media containing the above stimulants including IL-2 (20U/ml). After 48h the cells 
were washed extensively, transferred to fresh anti-CD3 coated microwell plates and 
cultured in IL-2 (20U/ml). Supernatants were collected after 48h of culture and cytokine 
production measured by enzyme-linked immunosorbent assay (ELISA). All stimulants 
were from BD Pharmingen unless stated otherwise. 
Sensitization and challenge protocols. 
To confirm the functional disruption of IL-4Rα specifically on B cells, mb1creIL-4Rα-/lox, 
IL-4Rα-/lox and IL-4Rα-/- mice were sensitized by intraperitoneal inoculation of 50μg 
ovalbumin in 1.5% aluminium hydroxide adjuvant (alum) (both Sigma-Aldrich, 
Germany). Mice were boosted at days 7 and 14, challenged by intranasal administration 
of 100μg ovalbumin at days 21, 22 and 23 and killed at day 25 for analysis. Control mice 
were treated with PBS-alum only. Oxazolone-mediated colitis was induced in BALB/c 
mice by modifying a previously described method (Neurath et al. 2002). Anesthetized 
mice were sensitized on the shaved abdomen by application of 3% oxazolone (4-
ethoxymethylene-2-phenyl-2-oxazolin-5-one; Sigma-Aldrich) in 100% ethanol (150µl) 
followed 7 days later by intrarectal administration of 1% oxazolone in 50% ethanol 
(150µl). Control mice were sensitized and challenged with ethanol only. Mice were 
killed 7 days post-challenge and immunopathological characterization was performed. 
To determine the role of IgE or IgG isotypes in oxazolone-induced colitis, in vivo 
neutralization was performed with 2 doses of anti-IgE (84.1C), anti-FcγRII/III (2.4G2) or 
rat anti-IgG control (afrc-mac51) (200μg/mouse), before sensitization and challenge with 
oxazolone (Figure 6A). 
Disease activity index (DAI). 
Oxazolone treated BALB/c mice develop rapid-onset colitis marked by weight loss and 
distress. To monitor disease progression, mice were weighed and monitored for distress 
and gastrointestinal symptoms 1-2 times daily. Weight loss was measured as a 
percentage of starting weight and distress was scored at day 2 post-challenge according 
to appearance, clinical signs and natural or provoked behaviour (Wolfensohn and Lloyd 
1998). Mice were scored on a scale of 0-16 and killed when the most severe score (16) 















10 mice/ group and the same criteria were monitored as mentioned above. Colon length 
was measured from the anus to the caecum and recorded as an indication of 
inflammation. 
Histological analysis 
Lung tissue or distal colon sections taken 1cm from the anus were fixed in ice cold 4% 
phosphate-buffered formalin to prevent tissue autolysis. Paraffin embedded tissue was 
cut into 2μm sections and stained with haematoxylin and eosin (H&E) for inflammatory 
cells, Periodic acid-Schiff reagent (PAS) for mucus producing goblet cells or toluidine 
blue for mast cells. Histopathological grading of oxazolone-induced colitis was adjusted 
from a previous study (Iijima et al. 2004) as described in chapter 2. Essentially, mice 
were graded on 5 criteria, 1) presence of mononuclear cells, 2) reduced goblet cells, 3) 
epithelial injury, 4) granulocyte infiltration and 5) oedema. Each criteria were scored 
from 0-3 and the total score was added resulting in a total additive score of between 0 
(no colitis) and 15 (maximal colitis activity). Histology sections were processed and 
stained by the Department of Surgery, Groote Schuur Hospital. 
Antibody detection by ELISA. 
Blood samples were taken by tail vein bleeding or directly from mice after killing and 
collected in gel separation tubes (Microtainer, BD, USA). Samples were centrifuged at 
4500rpm for 20min at 4°C. Ovalbumin-specific IgG1, IgG2a and IgG2b were measured 
by indirect ELISA using 5μg/ml ovalbumin for coating (overnight at 4°C) on nunc 
maxisorb ELISA plates (Nunc, Reskilde Denmark). The plates were blocked for 3h at 
37°C, washed 3x, serum added in serial dilutions and incubated overnight at 4°C.  
Alkaline Phosphatase (AP)-labelled goat-anti-mouse isotype-specific Abs (Southern 
Biotechnology, Birmingham, USA) were added for 1h at 37°C. Total IgE was measured 
by sandwich ELISA using clone 84.1C as a coat and anti-mouse IgE (Southern 
Biotechnology, USA) for detection (Nieuwenhuizen et al. 2007). Total IgE, IgG1, IgG2a 
and IgG2b levels were measured for naïve and oxazolone-treated mice (days 3 and 7) by 
sandwich ELISA. Anti-mouse IgE (84.1C), IgG1, IgG2a and IgG2b mAbs were used for 
coating, purified recombinant mouse IgE, IgG1, IgG2a and IgG2b (BD Pharmingen) 
were used as standards and anti-mouse isotype-specific Abs (Southern Biotechnology, 















1mg/ml in substrate buffer was added to all samples and the absorbance measured at 
405nm on a Versamax microplate spectrophotometer (Molecular Devices, Germany).  
Cellular restimulation and cytokine detection by ELISA. 
Mediastinal lymph node cells from ovalbumin sensitized mice were incubated at 1x106 
cells/ml on anti-CD3 coated plates (clone: 145-2C11, 10μg/ml) in IMDM with 10%FCS 
for 48h at 37°C and 5% CO2. Supernatants were collected and used for sandwich ELISA 
detection of cytokine levels (as above). Plates were coated with purified anti-IL-4 (clone: 
11B11, 2μg/ml), anti-IFN-γ (clone: An18KL6, 1μg/ml) or anti-IL-13 (clone: 38213, 
1μg/ml, BD Pharmingen) antibodies, blocked and serially diluted standards (purified 
recombinant IL-4, IFN-γ or IL-13) or cell supernatants were added. Biotinylated anti-
mouse secondary antibodies for IL-4 (clone: BVD6-24G2), IFN-γ (clone: XMG1.2) or 
IL-13 (goat anti-mouse, 0.5μg/ml, BD Pharmingen) were added for 3h at 37°C followed 
by horseradish peroxidise (HRP) labelled streptavidin. Subsequently, plates were 
developed with TMB Peroxidase Substrate (KPL, USA), the colour reaction stopped 
with 2M H2SO4 and absorption measured at 450nm.  
Cytokine detection in colon tissue homogenates by ELISA. 
Colon sections were pooled from oxazolone-treated and control mice, snap frozen in 
liquid nitrogen and stored at -80°C until analysis. Tissue sections were homogenized in 
PBS supplemented with protease inhibitors (Sigma, Germany) and normalised to 
10mg/ml protein using BCA protein assay kit (Pierce, Rockford, IL). IL-4, IL-13 and 
IFN-γ cytokines were measured as described above.  
Statistical analysis. 
Values are given as mean ± SEM, and significant differences were determined using 
unpaired two-tailed students t test or one-way ANOVA using a Bonferroni post-test 
















B cell-specific IL-4Rα deletion in mb1creIL-4Rα-/lox BALB/c mice. 
Conditional B cell-specific IL-4Rα-deficient BALB/c mice were generated by the 
Division of Immunology genotyping group as previously described for, 
macrophages/neutrophils and T cell subpopulations (Herbert et al. 2004; Radwanska et 
al. 2007; Dewals et al. 2009). Essentially, global IL-4Rα-/- mice (Mohrs et al. 1999) were 
intercrossed with transgenic mb1cre (Hobeika et al. 2006) and IL-4Rαlox/lox mice (Figure 
1A). Transgene-bearing B cell-specific IL-4Rα-deficient (mb1creIL-4Rα-/lox) mice were 
identified by PCR genotyping (Figure 1B). Primers targeting intron 6 and intron 10 of 
IL-4Rα, amplified product (471bp) in IL-4Rα-deleted mice (Deletion). In BALB/c mice, 
the targeted region was too large for PCR amplification. Mb1creIL-4Rα-/lox, IL-4Rα-/lox 
and global IL-4Rα-/- mice were positive for IL-4Rα deletion. Primers designed to flank 
the loxP insertion site amplified a 188bp product in “floxed” mice or a 94bp product in 
wild type BALB/c (IL-4Rα+/+) mice. The inserted hCre-transgene was amplified (500bp) 
in mb1creIL-4Rα-/lox but not IL-4Rα-/lox, BALB/c or global IL-4Rα-/- mice. These data 
confirm the successful generation of hCre transgenic, loxP flanked, B cell-specific IL-
4Rα disrupted mice. 
FACS analysis of IL-4Rα surface expression confirmed efficient deletion on B cells 
(CD19+ or B220+) isolated from spleen and bone marrow from mb1creIL-4Rα-/lox mice 
compared with IL-4Rα-/lox and IL-4Rα-/- controls. The cellular specificity of IL-4Rα 
deletion was confirmed because splenic T cells (CD3+, CD4+, CD8+ or NKT cells), 
natural killer cells (DX5+) and peritoneal macrophages (F4/80+) maintained IL-4Rα 
expression (Figure 1C). To establish the efficiency of IL-4Rα deletion at the genomic 
level from high purity (≥99%) FACS sorted cells; Real-Time quantitative PCR reactions 
were designed. Primers amplifying genomic regions of the IL-4Rα gene, affected or 
unaffected by the deletion were used (Radwanska et al. 2007). The number of exon 8 
alleles (one copy in -/lox and absent in -/- mice) relative to exon 5 alleles (both present in 
all cells) of IL-4Rα were determined in CD19+ and CD3+ cells (Figure 1D). Confirming 
FACS analysis, efficient deletion of loxP-flanked IL-4Rα exon 8 was observed in CD19+ 
B cells from mb1creIL-4Rα-/lox mice. As expected, no exon 8 product was visible in 
CD19+ and CD3+  cells of global IL-4Rα-/- mice, whereas an equivalent ratio of exon 8 











































































































































































































Figure 1: Generation of mb1creIL-4Rα-/lox mice. 
(A) Mouse breeding strategy. IL-4Rα-/- BALB/c mice were intercrossed with transgenic BALB/c mice 
expressing Cre-recombinase under control of the mb-1 promoter and IL-4Rαlox/lox mice to generate 
mb1creIL-4Rα-/lox mice. The “floxed” IL-4Rα allele (grey arrows) and deleted allele (black arrows) are 
shown.  
(B) Genotyping of transgene bearing B cell-specific IL-4Rα-deficient mice. The deleted IL-4Rα PCR 
yields a product of 471bp, loxP, 188bp (floxed), or 94bp (wild-type) and hCre-specific a 500bp product.  
(C) Phenotypic analysis. Spleen, bone marrow (BM) or peritoneal cells from naïve IL-4Rα-/lox (dotted 
line), IL-4Rα-/- (greyscale) and mb1creIL-4Rα-/lox (bold line) mice were stained for the surface expression of 
IL-4Rα.  B cells were CD19+/CD3- or B220+/CD3-, T cells were CD4+/CD3+ or CD8+/CD3+, natural killer 
T cells were DX5+/CD3+, natural killer cells were DX5+/CD3-, and macrophages were CD11b+/F4/80+. 
Data are representative of 3 independent experiments.  
(D) Efficiency of IL-4Rα-deletion. The ratio of IL-4Rα exon 5 and exon 8 alleles was determined by real- 
time PCR from genomic DNA purified from CD19+ or CD3+ cells. ND = samples not detected. 
(E) PCR products were visualized on an agarose gel. 1= IL-4Rα-/lox, 2= mb1creIL-4Rα-/lox and 3= IL-4Rα-/- 















PCR product size was confirmed on an agarose gel (Figure 1E). These data provide 
evidence of efficient deletion of IL-4Rα restricted to CD19+ B cells from mb1creIL-4Rα-
/lox mice. 
Selective impairment of IL-4Rα function in B cells. 
Th2 cells stimulate IL-4 responsive B cells to produce IgE or IgG1 antibodies. To 
determine if the absence of IL-4 signalling affects antibody production in naïve mice, 
serum was analysed for IgE, IgG1, IgG2a and IgG2b antibodies. Figure 2A shows that 
IL-4 responsive B cells are required for IgE and IgG1 production in both mb1creIL-4Rα-
/lox and IL-4Rα-/- mice and that without this signalling global IL-4Rα-/- mice have an 
increase in naïve levels of IgG2a. CD23 is the low affinity receptor for IgE and requires 
IL-4 to be expressed on mature B cells (Kijimoto-Ochiai 2002). FACS analysis showed 
the surface expression of this receptor to be reduced in the absence of IL-4Rα signalling 
on B cells, even in naïve mb1creIL-4Rα-/lox and IL-4Rα-/- mice compared with IL-4Rα-/lox 
mice (Figure 2B). These data suggest the functional disruption of IL-4Rα on B cells of 
mb1creIL-4Rα-/lox mice comparable to global IL-4Rα-deficient mice.   
IL-4 also induces the differentiation of naïve T cells into Th2 cells in vitro (Le Gros et 
al. 1990), while IL-12 drives Th1 development (Seder et al. 1993). We wanted to test 
whether deletion of IL-4Rα on B cells or the insertion of loxP sites on all cells had an 
effect on CD4+ T cell function. Therefore, naïve CD4+ T cells were stimulated with anti-
CD3/CD28 and treated with IL-12/anti-IL-4 to induce Th1 development or IL-4/anti-
IFN-γ to induce Th2 development. T cells were able to differentiate into Th1 or Th2 cells 
in both IL-4Rα-/lox and mb1creIL-4Rα-/lox mice (Figure 2C). This was in contrast to IL-
4Rα-/- mice, which only responded to IL-12 treatment.  
IL-4 also induces proliferation of naïve CD4+ T cells (Seder and Paul 1994). Naïve CD4+ 
T cells from IL-4Rα-/lox, IL-4Rα-/- and mb1creIL-4Rα-/lox BALB/c mice were stimulated 
with increasing doses of IL-4 or IL-2. DNA synthesis was measured by [3H] thymidine 
incorporation and showed that CD4+ T cells from IL-4Rα-/lox and mb1creIL-4Rα-/lox mice 
were able to proliferate in response to IL-4 in contrast to global IL-4Rα-/- mice (Figure 
2D). Impairment of IL-4 signalling was IL-4Rα specific, as proliferative responses to IL-
2, which shares a γc-chain with type I IL-4R, were unaffected in all three strains (Figure 
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Figure 2: Functional characterization of naïve mb1creIL-4Rα-/lox mice. 
(A) Impaired Type 2 antibody production. Total antibody levels were determined in the serum of naïve 
mice by ELISA and mean= ± SEM.  
(B) The low affinity IgE receptor (CD23) expression was determined by FACS analysis on naïve lymph 
node T and B cells. Geometric means are given of IL-4Rα-/lox (dotted line), IL-4Rα-/- (greyscale) and 
mb1creIL-4Rα-/lox (bold line) mice. 
(C) Normal Th2 differentiation. Th1 verses Th2 differentiation was promoted from naïve CD4+ T cells 
with IL-4/anti-IFN-γ or IL-12/anti-IL-4 mAbs. IFN-γ or IL-4 production was measured by ELISA. Values 
represent mean ± SEM from triplicate cultures. 
(D) CD4+ lymph node cells from naïve IL-4Rα-/lox, IL-4Rα-/- and mb1creIL-4Rα-/lox mice were stimulated 
with serial dilutions of IL-4 or (E) IL-2 (control). DNA synthesis was measured by [3H] thymidine 
incorporation. Data represents 2 independent experiments with * = p <0.05 and *** = p <0.001 vs. IL-4Rα-















B cell-specific IL-4Rα-deficient mice develop ovalbumin-induced allergy. 
IgE and IgG1 antibody secretion is dependant on IL-4 signalling on B lymphocytes 
(Shimoda et al. 1996). To show abrogated function of IL-4Rα on B lymphocytes, mice 
were sensitized with ovalbumin-alum at weekly intervals for 3 weeks and challenged 
intranasally with 100μg ovalbumin. Total serum IgE titres and antigen-specific IgG1, 
IgG2a and IgG2b were measured by ELISA. Mice treated with alum-only were included 
as a control and antibody levels were subtracted from experimental mouse groups. B 
cell-specific IL-4Rα-deficient mice had significantly reduced type 2 antibody levels (IgE 
and IgG1) with a shift towards type 1 antibody response (IgG2a and IgG2b), comparable 
to global IL-4Rα-/- mice (Grunewald et al. 1998) (Figure 3A). As expected IL-4Rα-/lox 
mice maintained a type 2 polarized antibody response to ovalbumin. 
Development of allergic asthma is driven by Th2 cytokines, especially IL-4, IL-5 and IL-
13. Therefore, mediastinal lymph nodes from ovalbumin-treated mice were restimulated 
with anti-CD3 and analyzed for cytokine production. Despite the reduced type 2 
antibody response by mb1creIL-4Rα-/lox mice, they maintained a Th2 polarized cytokine 
response with increased levels of IL-4, IL-5 and IL-13 comparable to IL-4Rα-/lox (Figure 
3B). Supporting the increased levels of type 1 antibodies, IL-4Rα-/- mice had 
significantly higher IFN-γ but reduced IL-4, IL-5 and IL-13 (Figure 3B). As the low 
affinity IgE receptor (CD23) is expressed on IL-4-activated B cells (Kijimoto-Ochiai 
2002), we wanted to determine if the lack of IL-4 signalling on mb1creIL-4Rα-/lox and IL-
4Rα-/- mice would effect CD23 surface expression by FACS analysis. Mesenteric lymph 
node, spleen and lung CD19+ cells showed a reduced surface expression of CD23 when 
compared with IL-4Rα-/lox mice (Figure 3C). No differences were detected in the surface 
expression on CD3+ lymph node cells in all three groups (Figure 3C).  
Lung histopathological analysis showed ovalbumin induced mucus hypersecretion by 
goblet cells and cellular infiltration in mb1creIL-4Rα-/lox and IL-4Rα-/lox mice, both 
common signs of allergic airway inflammation (Figure 3D). In IL-4Rα-/- mice, allergic 
reactions were completely abolished with no mucus production and low levels of cellular 
infiltration in the lungs, comparable to PBS/alum only control mice (Grunig et al. 1998) 
(Figure 3D). These results show that although B cell-specific IL-4Rα-deficient mice have 


















Figure 3: Impaired type 2 antibody response in an ovalbumin allergy model. 
(A) Mice were sensitized by i.p. injection for 3 weeks with ovalbumin and challenged by intranasal 
inoculation. Total IgE (ng/ml) or antigen-specific IgG1, IgG2a and IgG2b (OD at 1:1000) were measured 
by ELISA after killing the mice on day 25.  
(B) Mediastinal lymph nodes were restimulated with anti-CD3 and cytokine concentrations measured in 
the supernatant.  
(C) Impaired surface expression of the low affinity IgE receptor (CD23) was measured by FACS analysis 
on CD3+ and CD19+ mediastinal lymph node (MST), spleen and lung cells. IL-4Rα-/lox (dotted line), IL-
4Rα-/- (greyscale) and mb1creIL-4Rα-/lox (bold line). 
(D) Normal allergic response to ovalbumin. PAS stained histology sections showed mucus production by 
goblet cells (G) and cellular infiltration (I) in the lungs of ovalbumin sensitized IL-Rα-/lox and mb1creIL-
4Rα-/lox mice. Data represents 3 independent experiments (n=4), mean values are ± SEM and * = p <0.05, 
** = p <0.01 and ***= p <0.001 vs. IL-4Rα-/lox. 
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B cell-specific IL-4Rα-deficient mice are protected from oxazolone-induced colitis. 
Antibody-mediated hypersensitivity has long been considered a principal mediator of 
tissue damage in ulcerative colitis (UC) (Kett et al. 1987; MacDonald and Monteleone 
2006). B cell-specific IL-4Rα-deficient mice were generated using the Cre/loxP system 
with Cre-recombinase expression under control of the regulatory region for mb1. The 
mb1 gene encodes the Ig-α signalling subunit of the B cell antigen receptor and therefore 
resulted in IL-4Rα deletion specifically on B cells (Reth and Wienands 1997; Herbert et 
al. 2004; Hobeika et al. 2006). IL-4Rα-deletion on B cells was functionally characterized 
in a mouse model of allergy induced by ovalbumin. Considering the lack of IgE and 
IgG1 antibody response in a Th2 driven allergy model in novel mb1creIL-4Rα-/lox mice, 
we used an oxazolone-induced model of Th2 colitis (Boirivant et al. 1998; Heller et al. 
2002) to determine the role of IL-4 responsive B cells in UC. 
Oxazolone-treated mb1creIL-4Rα-/lox mice were significantly protected from rapid 
wasting disease (Figure 4A) and death (Figure 4B) induced in IL-4Rα-/lox mice. Distress 
was scored according to; appearance, clinical signs, natural and provoked behaviour and 
was reduced in B cell-specific IL-4Rα-deficient mice (Figure 4C).  The macroscopic 
appearance and length of the colon was normal in mb1creIL-4Rα-/lox mice with less 
inflammation-induced colon shortening (Figure 4D). For oxazolone-induced colitis in 
IL-4Rα-/lox control mice, the histopathological picture was similar to that seen in human 
UC, described by oedema, infiltration of granulocytes, epithelial layer disruption and 
loss of mucus production (Figure 4E). Colitis scoring proved mb1creIL-4Rα-/lox mice to be 
protected from the immunopathology associated with Th2 colitis, compared with IL-
4Rα-/lox mice (Figure 4F). Ethanol-only control mice showed no wasting disease and mild 
clinical and macroscopic symptoms of colonic inflammation. 
To address the impact of B cell-specific IL-4Rα-deficiency on Th2 effector functions, we 
measured total antibody response in the serum and tissue cytokine response in the colon 
tissue. As seen in the ovalbumin allergy model, reduced IgE and IgG1 levels were 
detected (Figure 5A) despite a maintained Th2 cytokine response (Figure 5B). This 
suggests that B cells signalling via the IL-4Rα to produce type 2 associated antibodies 
mediate oxazolone colitis. These data suggest that IL-4 responsive B cells and type 2 
















Figure 4: Mb1creIL-4Rα-/lox mice are protected from oxazolone-induced colitis. 
IL-4Rα-/lox or mb1creIL-4Rα-/lox BALB/c mice were presensitized 7 days before intrarectal challenge with 
oxazolone or ethanol-only control. 
(A) Wasting disease in oxazolone colitis. Weight loss was measured as a percentage starting weight for 3-7 
days post-challenge. (B) Mortality was recorded with 10 mice /group. (C) Distress was measured and mice 
were scored on appearance, clinical signs, natural and provoked behaviour (D) Macroscopic changes of 
colons in oxazolone-treated mice. Colon shortening and inflammation limited to the distal half are 
symptoms associated with colitis. (E and F) Reduced oxazolone-mediated histopathology. (E) Colonic 
sections from IL-4Rα-/lox or mb1creIL-4Rα-/lox mice administered oxazolone or ethanol only were stained 
with PAS. Representative photomicrographs (x40) are shown per group and presence of mononuclear cells 
( ), oedema (oed), SM =submucosa and M = mucosa are indicated (E). Semi-quantitative 
histopathological assessment of colitis activity was performed based on the presence of mononuclear cells, 
oedema, epithelial damage, loss of goblet cells and granulocyte infiltration (F). Data shown represents 
mean values ± SEM obtained from 2 independent experiments. Significance is compared with ethanol 
treated IL-4Rα-/lox mice, * = p <0.05 and *** = p <0.001 and IL-4Rα-/lox vs. mb1creIL-4Rα-/lox was and # = p 

























































































































































































































































Figure 5: Mb1creIL-4Rα-/lox mice have an impaired IgE response to oxazolone 
A) Impaired type 2 antibody response. Serum was collected from mice at day 3 post-challenge and total 
antibody levels were measured by ELISA.  
(B) Maintained Th2 cytokine response in the colon. Distal colon tissue was digested and prepared to 
measure cytokine levels in triplicate from pooled mice (n=4-8). Data represents 2 individual experiments 
with mean values ± SEM and * = p < 0.05, ** = p < 0.01 and *** = <0.001 vs. ethanol treated IL-4Rα-/lox 
















Anti-IgE treatment protects BALB/c mice from oxazolone-induced colitis. 
As mb1creIL-4Rα-/lox mice were protected from colitis and presented with undetectable 
IgE and reduced IgG1 levels, we examined the inhibitory effects of anti-IgE or anti-
FcγRII/III (for IgG isotypes) treatment on oxazolone-induced colitis in BALB/c mice. 
Mice were treated with blocking antibodies the day before sensitization or challenge with 
oxazolone (Figure 6A). Mice treated with anti-IgE were significantly protected from 
rapid wasting disease (Figure 6B) and death (Figure 6C) compared to wild type and anti-
rat IgG control BALB/c mice. Furthermore, the macroscopic appearance and length of 
the colon was normal in mice depleted of IgE with reduced inflammation-induced colon 
shortening (Figure 6D) and distress caused by the colitis (Figure 6E).  
Figure 7A shows that anti-IgE treatment effectively depleted IgE but did not 
significantly alter IgG levels. As seen in mb1creIL-4Rα-/lox mice, IL-4 cytokine levels 
remained elevated despite the undetectable IgE. In contrast, IL-13 production was 
reduced in mice treated with anti-IgE (Figure 7B).  
Photomicrographs showed IgE-depleted mice to be protected from the immunopathology 
associated with Th2 colitis, compared with wild type and control BALB/c mice (Figure 
8A). This was confirmed by scoring the colitis according to disease severity (Figure 8B). 
The high numbers of mast cells found in the gastrointestinal tract and their potency to 
release pro-inflammatory mediators, highlight them to be involved in intestinal 
pathologies (Bischoff and Gebhardt 2006). An increase in mast cell numbers have been 
observed in patients during active ulcerative colitis (Bischoff et al. 1996). Mast cells are 
activated by crosslinking of IgE receptor, therefore to determine a role for mast cells in 
oxazolone colitis we quantified the number of mast cells observed in oxazolone-treated 
BALB/c mice and compared these numbers to mice treated with anti-IgE. Histological 
sections of the distal colon were stained with toluidine blue to visualize intestinal mast 
cells (Figure 8C). Quantification of mast cells showed a significant increase in wild type 
and anti-rat IgG control BALB/c mice treated with oxazolone (Figure 8D). However, 
mice treated with antibodies against IgE had mast cell numbers comparable to ethanol-
only control mice. Together these data highlight a possible role for IgE (produced by IL-
4 responsive B cells) in recruiting and activating mast cells, therefore mediating the 
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Figure 6: Blocking IgE protects BALB/c mice from oxazolone-induced colitis. 
(A) BALB/c mice were treated with anti-IgE or control antibody one day before presensitized and again 
one day before intrarectal challenge with oxazolone or ethanol-only control. Mice were killed on day 3 
post-challenge or day 6 for survival studies. 
(B) Protection from wasting disease. Weight loss was measured as a percentage starting weight for 3 or 7 
days post-challenge. (C) Significantly reduced mortality was recorded after anti-IgE treatment with 10 
mice /group. (D) Protection from Macroscopic changes of colons in oxazolone-treated mice. Colon 
shortening and inflammation limited to the distal half of the colon were assessed.  
(E) Distress was measured and mice were scored on appearance, clinical signs, natural and provoked 
behaviour (day 2). Data shown represents mean values ± SEM obtained from 2 independent experiments 
from mice killed at day 3 unless stated otherwise. Significance is compared with ethanol treated BALB/c 









































































































































Figure 7: BALB/c mice treated with anti-IgE maintain a Th2 cytokine response. 
A) Impaired IgE but not IgG1 antibody response. Serum was collected from mice at day 3 post-challenge 
and total antibody levels were measured by ELISA.  
(B) Maintained IL-4 cytokine response in the colon. Colon tissue was digested and prepared to measure 
cytokine levels in triplicate from pooled mice (n=4-8). Data represents 2 individual experiments with mean 

















Figure 8: Depleting IgE reduces mast cell activation and oxazolone-induced colitis in BALB/c mice. 
IgE was blocked in BALB/c mice followed by sensitization and challenge with oxazolone or ethanol-only 
control. Mice were killed 3 days after challenge and colon sections were prepared to analyze oxazolone-
induced inflammation or mast cell numbers. Representative photomicrographs are shown.  
(A) Histological sections of colonic inflammation in IL-4Rα-/lox mice administered oxazolone or ethanol 
only and treated with anti-IgE or control were stained with PAS (x40). The presence of mononuclear cells 
( ), oedema (oed), submucosa (SM) and mucosa (M) are indicated. 
(B) Semi-quantitative histopathological assessment of colitis activity was performed based on the presence 
of mononuclear cells, oedema, epithelial damage, loss of goblet cells and granulocyte infiltration. (C) Mast 
cells ( ) were stained with toluidine blue (x100 and x400) and quantified per section. Goblet cells (G) are 
indicated (D). Data shown represents mean values ± SEM obtained from 2 independent experiments. 
Significance is compared with ethanol treated BALB/c mice, * = p < 0.05, ** = p < 0.01 and *** = p 
<0.001 and BALB/c vs. anti-IgE treated mice was # = p <0.05 and ### = p<0.001. 
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Ulcerative colitis has been associated with the production of IgG antibodies by plasma 
cells (MacDonald and Monteleone 2006). As mb1creIL-4Rα-/lox mice have reduced IgE 
and IgG1 levels we wanted to determine if IgG antibodies played a role in oxazolone- 
induced colitis. Therefore, we performed depletion studies using anti-FcγRII/III treated 
mice. Blocking FcγRII/III signalling had no effect on the outcome of disease in 
oxazolone-induced colitis with treated mice showing symptoms comparable to wild type 
or anti-rat IgG control BALB/c mice. Table 3 summarizes the results showing a 
significant weight loss comparable to oxazolone-treated wild type BALB/c mice.  
 
Table 3: Disease activity in oxazolone treated BALB/c mice treated with anti-FcRγII/III. 
 
Groups Body weight a Distress Scoreb Colon length Colitis Score 
IL-4Rα-/lox etoh 95.19 ± 2.1 3.61 ± 0.6 8.84 ± 0.3 4.20 ± 0.5 
IL-4Rα-/lox  oxa 82.61 ± 2.1 ** 12.81 ± 1.5 *** 6.57 ± 0.4 ** 9.67 ± 0.3 *** 
IL-4Rα-/lox  oxa + 
anti-FcγRII/III 
87.44 ± 1.4 * 10.00 ± 1.3 ** 7.00 ± 0.7 * 8.25 ± 0.8 ** 
a Body weight is shown as percentage starting weight 2 days post-challenge. 
b Distress is scored according to appearance, clinical signs, natural and provoked behaviour (day 2). 
c Colon length is measured in centimetres. 
* = p <0.05, ** = p <0.01 and *** = p <0.001 vs BALB/c etoh control. 
 
 
Furthermore, BALB/c mice treated with antibodies against FcγRII/III were significantly 
more distressed than ethanol-only control mice and showed colon shortening associated 
with inflammation comparable to oxazolone-treated BALB/c mice. Histology sections of 
the distal colon showed signs of colitis with an increase in the presence of mononuclear 
cells, goblet cell depletion, granulocytes (specifically neutrophils) infiltration and 
oedema. The levels of IgG antibodies in the serum were comparable to oxazolone-treated 
BALB/c mice because anti-FcγRII/III blocks the receptor of IgG antibodies. Therefore, 
these antibodies were produced in response to oxazolone but were unable to signal. 
These data suggest that IgG antibodies do not play a role in mediating oxazolone colitis 
















IL-4 and IL-13 regulate the function of many cell-types and are important in the 
generation of immunity in human diseases. Both IL-4 and IL-13 share a common 
signalling pathway through IL-4Rα (Nelms et al. 1999). By using Cre/loxP 
recombination to delete the IL-4Rα in cell-specific transgenic mice, the role of IL-4 
and/or IL-13 responsive B cells could be investigated. IL-13 has no functional receptor 
on T cells and mouse B cells were reported to be unresponsive to IL-13, however 
evidence suggests mouse IL-13 to enhance antibody production in vivo, therefore acting 
directly on B cells (Zurawski and de Vries 1994; Lai and Mosmann 1999; Mohrs et al. 
2000). By disrupting IL-4Rα specifically on B cells, the detrimental role of both IL-4 and 
IL-13 signalling on these cells could be investigated in a mouse model of ulcerative 
colitis. We described the generation, characterization and functional analysis of mice 
lacking the IL-4Rα chain selectively on B lymphocytes (mb1creIL-4Rα-/lox mice). In an 
allergic asthma model, mb1creIL-4Rα-/lox mice had an impaired type 2 antibody response 
to ovalbumin confirming functional disruption of IL-4Rα. However, these mice remained 
susceptible to the lung pathology associated with allergy and maintained a Th2 cytokine 
response. Mb1creIL-4Rα-/lox mice also had an impaired type 2 antibody response, with no-
IgE detectable in oxazolone-induced colitis and were significantly protected from disease 
onset. IgE was highlighted as a mediator of oxazolone-induced colitis as anti-IgE 
treatment protected BALB/c mice from developing disease.      
The novel B cell-specific IL-4Rα-deficient mouse strain (mb1creIL-4Rα-/lox) was 
generated using the Cre/loxP recombination system in BALB/c ES cells as previously 
demonstrated for macrophage/neutrophil- (Herbert et al. 2004), T cell- (Radwanska et al. 
2007; Dewals et al. 2009) and smooth muscle cell-specific (Horsnell et al. 2007) mice. 
The efficiency of B cell-specific IL-4Rα deletion was increased by mating IL-4Rα-/- with 
transgenic mb1cre mice, and then crossing them with IL-4Rαlox/lox mice, thereby reducing 
the loxP substrate for Cre-recombinase by 50%. PCR genotyping confirmed transgene-
bearing, hemizygous mb1creIL-4Rα-/lox mice and FACS analysis showed efficient B cell-
specific IL-4Rα disruption on spleen and bone marrow CD19+ and B220+ cells. The 
normal expression of IL-4Rα on T cell subpopulations, NK cells and macrophages 
confirmed the cellular specificity of disruption with functional analysis showing normal 
IL-4-driven proliferation and differentiation in CD4+ lymphocytes. Naïve wild type mice 















mb1creIL-4Rα-/lox naïve mice with very low levels of IgG1 suggesting a disruption of B 
cell function in response to IL-4.  
To functionally characterize the disruption of IL-4Rα on B cells in mb1creIL-4Rα-/lox 
mice, an in vivo model of allergic asthma in response to ovalbumin was induced. 
Comparison of these mice to IL-4Rα-/lox and IL-4Rα-/- controls showed that impaired IL-
4Rα signalling in B cells had no effect on the major symptoms of allergic asthma but that 
mb1creIL-4Rα-/lox mice had significantly reduced levels of Th2-associated antibodies (IgE 
and IgG1). The increase in type 1 antibodies (IgG2a and IgG2b) and trend to higher IFN-
γ, suggests that although these mice develop allergic asthma they show a shift towards a 
Th1 response. The maintained levels of Th2 cytokines, especially IL-13 would explain 
the ovalbumin-induced allergic response (Grunig et al. 1998; Wills-Karp et al. 1998). 
Furthermore, spleen, mediastinal lymph node and lung CD19+ cells showed impaired IL-
4 dependent surface expression of the low affinity receptor for IgE (CD23), supporting 
data that proved IL-4Rα to be functionally disrupted specifically on B cells (Kijimoto-
Ochiai 2002).  
Antibody-mediated hypersensitivity is a strong candidate for mediating tissue damage in 
UC. Even appendectomy has been shown to protect against the development of UC 
(Rutgeerts et al. 1994). It is suggested that the appendix plays a role in primary B cell 
development in rabbits (Pospisil and Mage 1998) and by removing it, the colon auto-
reactive or cross-reactive specificities would also be removed. This highlights a role for 
B cells in UC, however the mechanisms of their involvement and responsiveness to IL-
4/IL-13 is poorly understood. Colitis was induced in IL-4Rα-/lox BALB/c mice by 
intrarectal administration of oxazolone subsequent to skin sensitization. A chronic 
inflammation limited to the distal colon was obtained which proved to be similar to 
human UC in that it was relatively superficial, showed ulceration and had mixed 
inflammatory infiltrate of lymphocytes and granulocytes. As 50% ethanol alone has also 
been shown to induce a mild colitis in the colon, mice treated with ethanol-only were 
included as controls for all experiments (Andrade et al. 2003). 
Our research showed that mice with B cells unable to respond to IL-4/IL-13 were 
significantly protected from oxazolone-induced colitis. These mice maintained a Th2 
polarized response, demonstrated by increased IL-4 and IL-13 levels but had an 















highlighted the role of IL-13 producing NKT cells in oxazolone colitis (Heller et al. 
2002) but mb1creIL-4Rα-/lox mice have IL-13 and IL-4 levels comparable to IL-4Rα-/lox 
mice. Therefore, it is interesting that despite non-B cells maintaining their ability to 
respond to IL-13, the lack of type 2 antibodies was sufficient to confer protection from 
colitis in mb1creIL-4Rα-/lox mice. Given the heterogeneity of ulcerative colitis it is 
possible that blocking various signalling pathways at different stages of disease could 
equally protect from disease onset.  
Experimental models of anaphylaxis show both IgE-dependent and independent 
mechanisms, with the former inducing IgE cross-linking of FcεRI in mast cells (Coyle et 
al. 1996; Strait et al. 2002; Nieuwenhuizen et al. 2007). In a previous study, blocking 
IgE in mice sensitized with ovalbumin had no effect on the outcome of disease  
suggesting an IgE-independent anaphylaxis and supporting our data in which mb1creIL-
4Rα-/lox mice have abrogated IgE but still present with an allergic response 
(Nieuwenhuizen et al. 2007). In colitis, blocking IgE has been shown to reduce most of 
the clinical signs, such as weight loss, colon shortening, rectal bleeding and diarrhoea 
using the DSS-induced mouse model (Kang et al. 2006). DSS has been shown to induce 
both acute and chronic colitis in mice resembling UC with the acute phase being an 
innate, T and B cell independent response (Okayasu et al. 1990; Dieleman et al. 1994). 
Chronic DSS-induced colitis is characterized by focal epithelial regeneration and both 
Th1 and Th2 cytokine profiles (Dieleman et al. 1998). As oxazolone-induced colitis is 
commonly used to study the contribution of Th2-dependent immune responses to 
intestinal inflammation, we wanted to determine if blocking IgE would protect mice 
treated with oxazolone, confirming an IgE-dependent mechanism for oxazolone-induced 
colitis. It should be mentioned that oxazolone at low doses can also induce a mixed 
Th1/Th2-dependent colitis; therefore we sensitized BALB/c mice 7 days prior to 
challenge (Wirtz and Neurath 2007). 
Indeed our studies showed that blocking IgE significantly protected BALB/c mice 
against oxazolone-induced colitis with a corresponding reduction in mast cell numbers. 
This effect was IgE-dependent as blocking the FcγRII/III had no effect on the outcome 
of disease. In mice, the high affinity FcεRI receptor for IgE is limited to basophils and 
mast cells with mast cells being the major IgE-effectors whose function is to mediate 
cellular degranulation and release various inflammatory mediators (Kinet 1999).  In 















mast cell-mediated inflammatory factors, indicating that intestinal mast cell activation 
through FcεRI plays a role in the pathogenesis of UC (Kang et al. 2006). Furthermore, a 
recent study showing that oral antigen-induced intestinal and systemic anaphylaxis 
depends on IgE and mast cells and requires IL-9/IL-9R signalling (Osterfeld et al. 2010). 
This supports our observations and strengthens the importance of IgE highlighting a role 
for mast cells in regulating gut inflammation in UC. To determine if mast cells are 
indeed the cause of oxazolone-induced colitis further studies on mast cells will be 
required.  Such studies include, measurement of mouse mast cell protease-1 (MMCP-1) 
in the serum or mast cell depletion studies using anti-c-kit antibodies (McDermott et al. 
2003).  
In conclusion, our studies demonstrate that IL-4Rα expression on B cells plays a crucial 
role in mediating oxazolone-induced colitis. This colitis is IgE-dependent as blocking 
IgE confers protection from disease, while blocking the receptor for IgG antibodies has 
no affect on disease outcome. We also suggest a role for mast cells with increased 
numbers in susceptible oxazolone-treated BALB/c mice. These numbers are reduced by 
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Effector responses induced by polarized T helper 2 (Th2) cells drive the pathology 
associated with oxazolone-induced colitis in BALB/c mice. The Th2 cytokines IL-4 and 
IL-13 are known to mediate the immune response in the oxazolone mouse model of 
ulcerative colitis. However, the CD4+ T cell specific requirements of IL-4Rα signalling 
are unclear. The purpose of this study was to determine the mechanism of oxazolone-
induced colitis in gene-targeted mice with a deletion of the IL-4Rα chain specifically on 
CD4+ T lymphocytes (LckcreIL-4Rα-/lox). Expression of the IL-4Rα on CD4+ T cells was 
critical for colitis induction as LckcreIL-4Rα-/lox mice were protected from disease 
pathology shown by the amelioration of disease parameters including weight loss, 
survival, macroscopic inflammation, colitis shortening and histopathology. This 
protection was associated with reduced levels of IL-13 production. The importance of 
IL-4 responsive CD4+ T cells in mediating oxazolone colitis was confirmed by 
adoptively transferring CD4+/DX5- non-NK T cells into LckcreIL-4Rα-/lox mice to revert 
protection back to a susceptible phenotype in these mice. Together these data suggest 
that IL-4 responsive CD4+ T cells are crucial in mediating oxazolone-induced colitis 
















T cells have been linked to ulcerative colitis by the effectiveness of T cell-depletion 
therapy (Sawada et al. 2005) and ciclosporin treatment which reduces immune 
functioning of effector T cells (Lichtiger et al. 1994). Mouse models of Inflammatory 
Bowel Disease (IBD) have used T cell depletion and disruption of cytokine or cytokine 
receptor genes to show a disrupted T cell-dependent regulatory system. (Mombaerts et 
al. 1993; Morrissey et al. 1993; Sadlack et al. 1993; Strober and Ehrhardt 1993; Powrie 
1995; Suzuki et al. 1995; Takahashi et al. 1997). Lamina propria CD4+ T cells reacting 
to enteric flora are important effector cells causing mucosal inflammation in many 
experimental IBD models (Elson et al. 1995). Furthermore, studies of IBD in which 
CD4+ T cells are depleted in vivo, shows that inflammation is ameliorated (Simpson et 
al. 1995; Okamoto et al. 1999). Together these IBD models show that subpopulations of 
CD4+ T cells and their cytokines play a crucial role in the development of intestinal 
immune disorders.   
Hapten-induced mouse models of colitis are useful tools in understanding the 
mechanisms of mucosal inflammation. While trinitrobenzene sulphonic acid (TNBS)-
colitis is a Th1-mediated inflammation resembling human Crohn’s disease (CD), 
oxazolone-colitis is a Th2-mediated inflammation resembling human ulcerative colitis 
(UC) (Morris et al. 1989; Yamada et al. 1992; Boirivant et al. 1998).   Initial studies 
using a short-lived model of oxazolone colitis demonstrated that CD4+ T cells produce 
large amounts of IL-4 and IL-5 and that blocking IL-4 prevented colitis (Boirivant et al. 
1998). Subsequently, using a prolonged oxazolone colitis model, initial IL-4 production 
gave way to increasing levels of IL-13. By blocking IL-13 signalling with the soluble IL-
13Rα2-Fc, mice were protected from oxazolone-induced colitis. Furthermore, NK T cells 
producing IL-13 were highlighted as mediators of disease (Heller et al. 2002; Bouma and 
Strober 2003; Heller et al. 2005). The authors proposed that APCs or epithelial cells 
present antigen to NK T cells through CD1 and that NK T cells then produce IL-13. NK 
T cells can therefore have direct cytotoxicity against epithelial cells or IL-13 mediates 
disease by inducing epithelial cell apoptosis. However, NK T cells in this study also 
produced increased levels of IL-4 in response to αGalCer, a synthetic glycolipid that 
activates most invariant NK T cells (Kawano et al. 1997). Therefore, it is also possible 
that IL-4 plays a role in driving the initial inflammatory response to oxazolone and that 















investigate the role of IL-4 signalling on T cells during oxazolone-induced colitis we 
used mice deficient in the IL-4Rα specifically on CD4+ T cells (LckcreIL-4Rα-/lox).  
Previous studies in our lab have shown various roles for IL-4 responsive T cells in 
disease. LckcreIL-4Rα-/lox mice are protected from OVA-induced anaphylaxis despite the 
maintenance of a Th2 response (Nieuwenhuizen et al. 2007). These mice also survive 
acute schistosomiasis; where Th2 responses are essential for host survival (Leeto et al. 
2006). Furthermore, T cell responses to IL-4 are responsible for susceptibility to L. 
major infection (Radwanska et al. 2007) and are the cause of hypersensitivity to N. 
brasiliensis (Mearns et al. 2008). These studies highlight the possibility of a role of IL-4 
responsive CD4+ T cells in mediating a Th2 model of colitis.  
In this study, we addressed the role of CD4+ T cell IL-4Rα expression in UC. This was 
achieved by treating previously characterised LckcreIL-4Rα-/lox mice with oxazolone and 
monitoring disease outcome. Our results demonstrate that LckcreIL-4Rα-/lox mice were 
significantly protected from the pathology associated with oxazolone colitis, indicating a 
role for IL-4 responsive CD4+ T cells in mediating disease. To confirm that these cells 
do indeed drive pathology, we adoptively transferred IL-4 responsive CD4+ T cells from 
IL-4Rα-/lox littermate controls into LckcreIL-4Rα-/lox mice and were able to revert 
protection back to a susceptible phenotype. As a subpopulation of NK T cells are also 
CD4 positive (Kronenberg and Gapin 2002), we confirmed the disease pathology to be 
mediated by CD4+ non-DX5+ NK T cells, by transferring CD4+/DX5- sorted cells back 
into LckcreIL-4Rα-/lox mice and inducing pathology. These data suggest a potential role 















MATERIALS AND METHODS 
Mice.  
The generation and characterization of CD4+ T cell-specific IL-4Rα-deficient (LckcreIL-
4Rα-/lox) mice was previously described (Radwanska et al. 2007). Briefly as described in 
chapter 2, Lckcre mice on a BALB/c background were crossed with IL-4Rα-/- mice 
(Mohrs et al. 1999) and IL-4Rαlox/lox mice (Herbert et al. 2004) to generate LckcreIL-4Rα-
/lox mice. Male mice (6-8 weeks old) were genotyped by PCR to confirm CD4+ T cell-
specific disruption of IL-4Rα and hemizygous IL-4Rα-/lox littermates were used as 
control groups in oxazolone colitis experiments. All mice were housed in specific 
pathogen-free conditions at the University of Cape Town, South Africa and experiments 
were approved by the University’s Animal Ethics Committee. 
Oxazolone-induced colitis and adoptive transfer of CD4+ or CD4+/DX5- cells. 
LckcreIL-4Rα-/lox and IL-4Rα-/lox littermate control mice were treated with oxazolone as 
described in chapters 2 and 3. Anesthetized mice were sensitized with 3% oxazolone in 
100% ethanol (150µl) followed 7 days later by intrarectal administration of 1% 
oxazolone in 50% ethanol (150µl). Mice were monitored daily for weight loss and killed 
3 days post-challenge for immunopathological analyses or 7 days post-challenge for 
survival studies. For adoptive transfer studies, lymphocytes from IL-4Rα-/lox mice were 
FACS sorted for CD4+ (clone: GK1.5) or CD4+/DX5- (clone: DX5) cells (>98% purity). 
Biotin-labelled antibodies were detected by streptavidin-APC and anti-FcγRII/III (clone: 
2.4G2) was used to block non-antigen-specific binding of immunoglobulins to FcγII and 
FcγIII receptors. Antibodies were from BD Pharmingen (San Diego, CA). Mice received 
1x106 sorted cells 24hr prior to sensitization with oxazolone (see Appendix A for 
additional reagents for all experiments). 
Disease activity index (DAI). 
Oxazolone-treated IL-4Rα-/lox control mice develop rapid-onset colitis marked by weight 
loss and distress as described in chapters 2 and 3. Essentially, disease progression was 
monitored by weight loss as a percentage starting weight and distress scored at day 2 
post-challenge (see Table 1 of Appendix A) (Wolfensohn and Lloyd 1998). Survival 
studies were performed with 10 mice/ group and the same criteria were monitored as 
mentioned above. Colon length was measured from the anus to the caecum and recorded 















Histological assessment of colitis. 
Distal colon sections taken 1cm from the anus were fixed in ice cold 4% phosphate-
buffered formalin to prevent tissue autolysis. Histology sections were processed and 
stained with haematoxylin and eosin for inflammatory cells or PAS reagent for mucus 
producing goblet cells. Semi-quantitative histopathological grading of oxazolone-
induced colitis was adjusted from a previous study, (Iijima et al. 2004) with 5 criteria 
(presence of mononuclear cells, reduced goblet cells, epithelial injury, granulocyte 
infiltration and oedema). Each were scored from 0-3 with an additive score of between 0 
(no colitis) and 15 (maximal colitis activity). 
Isolation and restimulation of splenocytes. 
As described in chapters 2 and 3, individual or pooled spleens from oxazolone treated 
mice were collected in complete IMDM supplemented with 10% FCS, penicillin, 
streptomycin, 1mM sodium pyruvate, 50μM β2-ME and NEAA. Viable single cells 
(depleted of RBCs) were diluted to 1x106 cells/ml and cultured in complete IMDM with 
anti-CD3 (10μg/ml) for 48h at 37°C and 5% CO2. Supernatants were collected and 
stored at -80°C.  
Cytokine and total IgE detection by ELISA. 
Sandwich ELISAs were performed to determine cytokine levels in cell supernatants and 
total serum IgE levels as described in chapters 2 and 3. Essentially, microtitre plates 
were coated with purified anti-IL-4, anti-IFN-γ, anti-IL-13 or anti-IgE antibodies, diluted 
in PBS. Serially diluted recombinant IL-4, IFN-γ, IL-13 or IgE standards, cell 
supernatants or serum was added. Biotinylated anti-mouse secondary antibodies for IL-4, 
IFN-γ, IL-13 or IgE were added followed by HRP labelled streptavidin for detection. 
Subsequently, plates were incubated with TMB Peroxidase Substrate, the colour reaction 
stopped with 2M H2SO4 and absorption measured at 450nm. ELISA wash buffer was 
used to wash plates 4x between each step. 
Statistical analysis. 
Values are given as mean ± SEM, and significant differences were determined using 
unpaired two-tailed students t test or one-way ANOVA using a Bonferroni post-test 

















CD4+ T cell-specific IL-4Rα-deficient mice are protected from oxazolone colitis. 
As murine T lymphocytes do not have a functional IL-13 receptor (Zurawski and de 
Vries, 1994) specifically deleting the IL-4Rα from CD4+ T cells will determine a role for 
IL-4 responsive T cells during oxazolone-induced colitis. Therefore we treated mice 
deficient in IL-4Rα on CD4+ T cells (LckcreIL-4Rα-/lox) to determine the role of IL-4 
responsive CD4+ T cells in oxazolone-induced colitis. 
Previously characterised LckcreIL-4Rα-/lox mice have complete disruption of IL-4Rα on 
CD4+ T cells with variable deletion efficiency on CD8+, γδ+ and NK T cells (Radwanska 
et al. 2007). LckcreIL-4Rα-/lox mice were protected from oxazolone-induced colitis shown 
by comparable weight loss (Figure 1A) and survival (Figure 1B) to ethanol-treated 
control IL-4Rα-/lox mice. The macroscopic appearance and length of the colon was 
normal in LckcreIL-4Rα-/lox mice with less inflammation-induced colon shortening 
(Figure 1C). Distress was scored according to appearance, clinical signs, natural and 
provoked behaviour, and was significantly reduced in LckcreIL-4Rα-/lox mice (Figure 1D).  
Although LckcreIL-4Rα-/lox mice showed mild symptoms of pathology, with some 
inflammatory cell infiltration and oedema, the colitis score in these mice remained 
significantly lower than oxazolone-treated IL-4Rα-/lox control mice (Figure 1E and 1F). 
The protection of LckcreIL-4Rα-/lox mice from oxazolone-induced colitis was associated 
with significantly reduced levels of IL-4 and IL-13 cytokine production and normal 
levels of IFN-γ (Figure 2A). As previously shown in response to N. brasiliensis, 
LckcreIL-4Rα-/lox mice maintained production of IgE despite reduced levels of IL-4 

















Figure 1: LckcreIL-4Rα-/lox mice are protected from oxazolone-induced colitis. 
CD4+ T cell-specific IL-4Rα-deficient BALB/c mice were pre-sensitized with 3% oxazolone (oxa) in 
100% ethanol before intrarectal challenge with 1% oxa in 50% ethanol (LckcreIL-4Rα-/lox oxa). Littermate 
control mice were administered ethanol only (IL-4Rα-/lox etoh). LckcreIL-4Rα-/lox mice were protected from 
rapid onset of colitis induced by oxazolone shown by: (A) Significantly reduced weight loss as percentage 
starting weight and (B) prolonged survival compared with IL-4Rα-/lox controls treated with oxazolone (day 
7). (C) Normal colon appearance in macroscopic pictures with normal colon length, indicating reduced 
inflammation. (D) Significantly less distress, scored according to severity of symptoms with a maximum 
score of 16 at day 2 post-challenge. (E) Significantly reduced colitis score from pooled experiments. (F) 
Reduced or no oxazolone-induced inflammation shown in PAS-stained sections of the distal colon, while 
IL-4Rα-/lox mice show oedema (oed), reduced mucous production and inflammatory infiltrates ( ). SM 
=submucosa and M =mucosa. All data represents mice killed 3 days post-challenge unless indicated. Data 
represents 3 individual experiments (n=4-8 mice) with mean values ± SEM and * = p <0.05, ** = p <0.01 
and *** = p <0.001 vs. IL-4Rα-/lox etoh controls and # = p <0.05 and ## = p <0.01 IL-4Rα-/lox vs. LckcreIL-
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Figure 2: Impaired Th2 response to oxazolone in LckcreIL-4Rα-/lox mice. 
Systemic T lymphocyte responses were assessed from spleen cells of oxazolone treated CD4+ T cell-
specific IL-4Rα-deficient mice and compared to oxazolone treated or control IL-4Rα-/lox littermates. 
(A) Cytokine production from restimulated splenocytes was analysed by ELISA showing significantly 
reduced IL-4 and IL-13 production with little or no effect on IFN-γ levels. (B) Despite reduced levels of 
IL-4 and IL-13, LckcreIL-4Rα-/lox mice were able to produce IgE antibodies in response to oxazolone 
treatment. Total IgE levels were determined by ELISA from the serum of experimental mice 3 days post-
challenge (10 days post-sensitization). Data represents 2 individual experiments (n =4-8), with mean ± 
SEM and * = p <0.05 and ** = p <0.01 vs. IL-4Rα-/lox etoh mice and # = p <0.05 and ## = p <0.01 IL-4Rα-


















IL-4 responsive CD4+ T cells mediate oxazolone-induced colitis. 
We showed that BALB/c mice with CD4+ T cells unable to respond to IL-4 (LckcreIL-
4Rα-/lox) were protected from oxazolone-induced colitis suggesting that IL-4 responsive 
CD4+ T cells mediate colitis. To confirm this data we therefore adoptively transferred IL-
4 responsive CD4+ T cells from IL-4Rα-/lox into LckcreIL-4Rα-/lox mice to determine 
whether we could revert these mice back to the disease phenotype seen in IL-4Rα-/lox 
mice.  
Indeed, LckcreIL-4Rα-/lox mice receiving IL-4 responsive CD4+ T cells developed 
oxazolone-induced colitis. This was shown with weight loss comparable to oxazolone-
treated IL-4Rα-/lox mice (Figure 3A) and a similar mortality rate (Figure 3B). Ethanol 
treatment alone has also been shown to induce a mild form of colitis in the colon. This 
was evident in the mortality rate of IL-4Rα-/lox mice treated with ethanol-only as a 
negative control (Figure 3B). LckcreIL-4Rα-/lox mice receiving IL-4 responsive CD4+ T 
cells were significantly distressed compared to ethanol-only control mice (Figure 3C) 
with colon shortening comparable to oxazolone-treated IL-4Rα-/lox mice (Figure 3D). IL-
4 and IL-13 production by spleen cells was significantly increased in LckcreIL-4Rα-/lox 
mice which received CD4+ T cells compared with ethanol-only control mice, while IFN-
γ production remained unchanged (Figure 3E). Although the level of these Th2 cytokines 
were lower than oxazolone treated IL-4Rα-/lox mice, the small amounts produced were 
sufficient to drive the pathology associated with oxazolone colitis. 
These data confirm the importance of CD4+ T cells in mediating oxazolone-induced 
colitis. However, it does not rule out the possibility that CD4+ NK T cells are in fact 
driving the pathology associated with oxazolone colitis or that the action of transferring 
cells alone is causing some form of pathology. Therefore we planned to transfer 
CD4+/DX5- T cells to all mouse groups to determine if IL-4 responsive NK T cells are 

























































































































































































































Figure 3: IL-4 responsive CD4+ T cells mediate oxazolone-induced colitis in LckcreIL-4Rα-/lox mice. 
CD4+ T cells from IL-4Rα-/lox mice were sorted by FACS (>98% purity) and adoptively transferred into 
LckcreIL-4Rα-/lox mice. Control IL-4Rα-/lox mice administered ethanol-only or oxazolone also received 
CD4+ cells. Oxazolone-treated mice were treated as described above with pre-sensitization and challenge 
steps. CD4+ T cells were able to mediate the onset of oxazolone-induced colitis in LckcreIL-4Rα-/lox mice 
shown by; (A) Significant weight loss as percentage starting weight. (B) Increased mortality comparable to 
oxazolone-treated IL-4Rα-/lox control mice (day 7). (C) Significant distress compared with IL-4Rα-/lox 
ethanol controls, scored according to severity of symptoms with a maximum score of 16 at day 2 post-
challenge. (D) Reduced colon length indicating inflammation.  
(E) Systemic T lymphocyte responses were assessed from restimulated splenocytes of oxazolone treated 
mice and showed IL-4 and IL-13 production to be lower than oxazolone-treated control mice but 
maintained a polarized Th2 response (E). No significant difference was detected in IFN-γ production. 
All data represents mice killed 3 days post-challenge unless indicated. Data represents 2 individual 
experiments (n=4-8 mice) with mean values ± SEM and * = p <0.05, ** = p <0.01 and *** = p <0.001 vs. 















IL-4 responsive NK T cells are not essential in oxazolone-induced colitis. 
Previous studies have suggested that experimental and human ulcerative colitis is 
mediated directly by NK T cells, described as CD4+ T cells bearing NK markers, in the 
lamina propria (Heller et al. 2002; Fuss and Strober 2008). These NK T cells could be 
activated to secrete IL-13, which may bring about changes in the epithelial barrier 
function or have direct cytotoxic effects on epithelial cells. In oxazolone-induced colitis 
IL-4 is produced initially and then superceded by increased IL-13 production (Heller et 
al. 2002). Our data suggests a role for IL-4 responsive CD4+ T cells in mediating 
oxazolone colitis; however we could not eliminate the possibility that these are CD4+ NK 
T cells. To determine if oxazolone colitis could be induced in mice lacking IL-4 
responsiveness on CD4+ non-NK T cells, we adoptively transferred CD4+DX5- T cells 
expressing IL-4Rα into protected LckcreIL-4Rα-/lox mice and IL-4Rα-/lox mice treated with 
or without oxazolone as controls.  
Our data show that CD4+ non-NK T cells mediate oxazolone-induced colitis. This is 
shown by significant weight loss presented as a percentage starting weight (Figure 4A) 
and significant distress (Figure 4B). Macroscopic examination three days post-challenge 
showed severe colitis limited to the distal half of the colon (Figure 4C) with 
inflammation associated colon shortening compared with ethanol-only control mice 
(Figure 4D). Microscopic examination of the distal colon showed superficial 
inflammation characterized by epithelial cell loss, patchy ulceration and pronounced 
depletion of mucous producing-goblet cells (Figure 4E), confirmed by semi-quantitative 
histopathological assessment (Figure 4F). Although the systemic levels of IL-4 
production remained low, IL-13 was increased and associated with oxazolone-induced 
pathology in LckcreIL-4Rα-/lox mice treated with IL-4 responsive CD4+ non-NK T cells 
(Figure 5A). As IFN-γ production has been shown to be variable in the oxazolone colitis 
model depending on dose and time point of detection, the elevated levels in both 
oxazolone treated groups is not unexpected (Figure 5B). 
Together these data strongly suggests that IL-4 responsive CD4+ non-NK T cells are 
involved in mediating oxazolone-induced colitis. Although T lymphocytes are thought 
not to have a functional IL-13 receptor, the possibility that IL-13 signals via the newly 

















Figure 4: IL-4 responsive DX5+ NK T cells are not essential in oxazolone-induced colitis. 
As CD4 is expressed on some NK T cells we sorted CD4+/DX5- T cells by FACS (>98% purity) to exclude 
the possibility of NK T cells mediating oxazolone-induced colitis. Therefore, CD4+/DX5- T cells were 
adoptively transferred into LckcreIL-4Rα-/lox mice. Control IL-4Rα-/lox mice administered ethanol-only or 
oxazolone also received CD4+/DX5- T cells. CD4+/DX5- T cells maintained their ability to mediate the 
onset of oxazolone-induced colitis in LckcreIL-4Rα-/lox mice shown by; (A) Significant weight loss as 
percentage starting weight. (B) Significant distress compared with IL-4Rα-/lox ethanol controls, at day 2 
post-challenge. (C) Macroscopic appearance of inflammation limited to the distal colon. (D) Reduced 
colon length.  (E) Inflammation shown in PAS-stained sections of the distal colon, oedema (oed), 
inflammatory infiltrates ( ), SM =submucosa and M =mucosa and confirmed by semi-quantitative 
histopathological assessment (F). All data represents mice killed 3 days post-challenge unless indicated. 
Data represents 1 individual experiment (n=5-8 mice) with mean values ± SEM and * = p <0.05, ** = p 
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Figure 5: IL-4 responsive CD4+/DX5- T cells induce IL-13 production in oxazolone-treated LckcreIL-
4Rα-/lox mice. 
Systemic T lymphocyte responses were assessed from spleen cells of oxazolone-treated LckcreIL-4Rα-/lox 
mice which received CD4+/DX5- T cells by adoptive transfer.  
(A) Systemic cytokine production from restimulated splenocytes was analysed by ELISA showing 
significantly reduced IL-4, but maintained compared to IL-4Rα-/lox littermate control mice treated with 
oxazolone. (B) IFN-γ production was elevated in both mouse groups treated with oxazolone compared to 
ethanol-only control mice. Data represents 1 individual experiment (n =5-8) of mice killed on day 3, with 
mean ± SEM and * = p <0.05 and ** = p <0.01 vs. IL-4Rα-/lox etoh mice and # = p <0.05 IL-4Rα-/lox vs. 




















In the present study we describe a BALB/c model of ulcerative colitis mediated by IL-4 
responsive CD4+ non-NK T cells. Experimental models of IBD allow us to elucidate 
cellular and molecular mechanisms of disease pathology. Previous studies showed direct 
involvement of CD4+ T cells in colitis by adoptively transferring CD45 RBhigh CD4+ T 
cells into skid mice to induce intestinal inflammation (Powrie et al. 1994; Powrie 1995). 
In this model, the transfer of DX5+ NKT cells reduced established colitis suggesting a 
regulatory role for these cells in a chronic type 1-mediated colitis (Hornung et al. 2006). 
Furthermore, CD4+ TCRα-β+ T cells mediate the development of UC in TCRα-/- mice 
(Mombaerts et al. 1993; Viney et al. 1994; Takahashi et al. 1997). While IL-4 mediates 
multiple effects on murine T cells, these cells do not respond to IL-13 (Zurawski and de 
Vries 1994). Therefore, the availability of CD4+ T cell-specific IL-4Rα-deficient mice 
(LckcreIL-4Rα-/lox) allows investigation of the role of IL-4 signalling specifically on 
CD4+ T cells while maintaining IL-4/IL-13-mediated functions on non-CD4+ T cells.  
Previously characterized and published LckcreIL-4Rα-/lox mice (Nieuwenhuizen et al. 
2007; Radwanska et al. 2007; Dewals et al. 2009) were sensitized and challenged with 
oxazolone. Our data shows these mice to be significantly protected from oxazolone-
induced colitis shown by the amelioration of disease parameters including weight loss, 
survival, macroscopic inflammation, colitis shortening and histopathology. Abrogated 
disease pathology in LckcreIL-4Rα-/lox mice was associated with a decrease in IL-13 
production by spleen cells. Although IL-13 is thought to be the major player in 
oxazolone colitis, IL-4 is also able to disrupt epithelial cell tight junctions (Ceponis et al. 
2000). The data in chapter 2 of this thesis show that IL-4-/- BALB/c mice are partially 
protected from colitis. These mice have significantly increased levels of IL-13 after 
oxazolone treatment, whereas LckcreIL-4Rα-/lox mice have IL-13 levels comparable to 
ethanol-only control mice. Therefore it remains likely that IL-13 is the primary mediator 
of colitis with the low levels of IL-13 in LckcreIL-4Rα-/lox mice responsible for attenuated 
disease development. These data also suggest that IL-4 signalling through non-CD4+ T 
cells may regulate IL-13 production.  
To confirm the role of IL-4 responsive CD4+ T cells in oxazolone colitis we adoptively 
transferred these cells back into LckcreIL-4Rα-/lox mice and were able to drive oxazolone-
induced colitis. These data demonstrate the importance of IL-4 responsive CD4+ T cells 















cells and CD4+ NK T cells. Therefore, we attempted to deplete NK T cells by FACS 
sorting for CD4+/CD49b- (DX5) lymphocytes. There is controversy about whether 
CD49b (DX5) suitably identifies subpopulations of NK T cells, as only a minority of 
DX5+ cells are CD1d-dependent (Pellicci et al. 2005). However, most CD1d-dependent 
NK T cells express DX5 (Pellicci et al. 2005) therefore we depleted NK T cells by 
removing CD4+/DX5+ T cells. Adoptive transfer of IL-4 responsive CD4+ non-DX5+ NK 
T cells into LckcreIL-4Rα-/lox mice resulted in oxazolone-induced colitis, suggesting an 
important role for these cells in disease pathology. Furthermore, LckcreIL-4Rα-/lox mice 
which received these cells produced significantly increased levels of IL-13 highlighting 
the possible importance of IL-13 in disease progression. 
Athough IL-13 production by NK T cells has been shown to mediate oxazolone-induced 
colitis, our data show that IL-4 responsive CD4+ non-NK T cells are also important in 
mediating disease. Whether this occurs before or after NK T cell activation and IL-13 
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Animal models have played an important role in understanding the underlying 
mechanisms of pathogenesis in ulcerative colitis. The main focus of this project was to 
investigate the role of Th2 cytokines and the receptors through which they signal in a 
mouse model of UC induced by oxazolone. By using a combination of IL-4, IL-13 and 
IL-4Rα-deficient mice, the first study suggests a possible role for IL-13 signalling 
independently of the IL-4Rα in mediating colonic inflammation. In the second study, we 
characterized a novel genetic mouse model in which IL-4Rα was specifically deleted on 
B cells (mb1creIL-4Rα-/lox). By using these mice in the oxazolone-induced colitis model 
we could demonstrate that IL-4 responsive B cells are involved in driving the disease. As 
mb1creIL-4Rα-/lox mice failed to launch an IgE response to oxazolone treatment we 
investigated whether IgE is critical for colitis pathology. Indeed, depleting IgE from 
BALB/c mice significantly protected them from the onset of colitis with reduced mast 
cell numbers in the distal colon. In the third study, we used a previously characterized T 
cell-specific IL-4Rα-deficient mouse (LckcreIL-4Rα-/lox). Our data showed that IL-4 
responsive CD4+ T cells were critical for colitis induction as LckcreIL-4Rα-/lox mice were 
protected from disease pathology. We confirmed the importance of IL-4 responsive 
CD4+ T cells but not CD4+DX5+ NK T cells by adoptively transferring IL-4Rα 
expressing CD4+DX5- T cells into LckcreIL-4Rα-/lox mice and managed to reverse 
protection back to a susceptible phenotype.  
Combining our data with previous studies, a hypothetical model can be drawn on the 
possible mechanisms involved in the pathogenesis of oxazolone colitis (Figure 1). 
Essentially, commensal bacteria products stimulate epithelium or the mucosal immune 
system by penetrating the mucosal barrier. Antigen presenting cells (APCs) or direct 
stimulation from epithelial cells activates NK T cells to drive a Th2/type 2 response. 
Alternatively, APCs stimulate Th0 cells to drive a Th2 response, subsequently activating 
NK T cells as a downstream effect. Together these NK T cells or IL-4 dependent Th2 
cells drive the pathology associated with oxazolone colitis. NK T and Th2 cells both 
produce IL-13 which is toxic to epithelial cells. Furthermore, IL-13 signalling via the IL-
13Rα2 induces an inflammatory response. Lastly, Th2 cells produce IL-4 which 










































Figure 1: Hypothetical model of the pathogenesis of oxazolone colitis. 
Commensal bacteria products stimulate epithelium or the mucosal immune system by penetration of the 
mucosal barrier. Antigen presenting cells (APCs) or direct stimulation from epithelial cells activate NK T 
cells to drive a Th2/type 2 response. Alternatively activated Th0 cells can drive a Th2 response, 
subsequently activating NK T cells. NK T and Th2 cells produce IL-13 which is toxic to epithelial cells. 
IL-13 signalling via the IL-13Rα2 induces an inflammatory response. Lastly, Th2 cells produce IL-4 which 















In study one, our data confirms previous studies showing the importance of IL-4 and IL-
13 production in oxazolone-induced colitis. However we show for the first time that by 
blocking the receptor through which these cytokines signal (IL-4Rα) disease was 
exacerbated. Furthermore, we demonstrate that IL-13 mediates colitis in IL-4Rα-/- and 
wild type mice, as disrupting IL-13 but not IL-4 production in BALB/c and IL-4Rα-/- 
mice rescues them from the pathology associated with oxazolone colitis. This suggests a 
role for IL-4Rα-independent signalling of IL-13 to induce colitis. Although IL-13 clearly 
drives pathology, the source of this IL-13 is yet to be defined. As shown in our data, 
many cell types express the IL-13Rα2. However, further studies are required to 
determine if cells expressing IL-13Rα2 are responsible for inducing the pathology of 
oxazolone colitis. As epithelial cells have been shown to express IL-13Rα2 (Donaldson 
et al. 1998), studies isolating these cells and measuring the effect of IL-13 on IL-13Rα2 
expression would be of interest. Our results also show the downregulated expression of 
IL-13Rα2 on neutrophils in oxazolone treated mice. IL-13 has been shown to activate 
neutrophils and it would be interesting to determine if these effects are related to the IL-
13Rα2 (Girard et al. 1996).  
In study two, we demonstrate that mice deficient in IL-4Rα specifically on B cells 
(mb1creIL-4Rα-/lox) are significantly protected from oxazolone-induced colitis. These 
mice had reduced levels of IgE and IgG1. Furthermore, blocking IgE protects BALB/c 
mice from oxazolone colitis with reduced mast cell numbers. Therefore, IgE production 
by IL-4 responsive B cells induces inflammation in response to oxazolone. Although we 
were able to detect increased mast cell numbers in the distal colon of oxazolone-treated 
mice, further analysis would be useful in determining mast cell activation. Once 
degranulation occurs mast cells are not seen in histology sections, but mast cell-derived 
mediators such as tryptase and TNF-α can be detected in tissue samples. To effectively 
determine the importance of mast cells in oxazolone colitis, mast cell depletion studies 
would be advantageous. Furthermore, staining for IgE in the distal colon, could 
determine the localization of IgE in the inflamed tissue. Interestingly, although IL-4Rα-/- 
mice have no detectable levels of IgE (Experimental study 1, Figure 6), they show 
exacerbated disease. It is possible that the regulatory role of non-T and B cells in 
















In study three, we addressed the role of IL-4 responsive CD4+ T cells in oxazolone 
colitis. Our results demonstrate the significant protection of LckcreIL-4Rα-/lox mice from 
the pathology associated with oxazolone colitis, indicating a role for IL-4 responsive 
CD4+ T cells in mediating disease. To confirm that these cells do indeed drive pathology, 
we adoptively transferred IL-4Rα expressing CD4+ T cells from IL-4Rα-/lox littermate 
controls into LckcreIL-4Rα-/lox mice and were able to revert protection back to a 
susceptible phenotype. As a subpopulation of NK T cells are also CD4 positive, we 
confirmed the disease pathology to be mediated by IL-4Rα expressing CD4+DX5- T cells 
by removing CD4+DX5+ (NK T cells), before adoptive transfer. These data suggest a 
potential role for IL-4 responsive CD4+ but not NK T cells in mediating oxazolone-
induced inflammation. Previous studies have highlighted the role of NK T cells in 
oxazolone colitis; however our data suggests that the pathogenesis is dependent on CD4+ 
T cells expressing IL-4Rα. It is possible that NK T cells induce the pathology associated 
with colitis by driving CD4+ T cells to produce IL-13. However the reverse would also 
be possible, with CD4+ T cells driving NK T cells to induce pathology. Therefore, 
depletion of NK T cells or blocking IL-13 would also result in protection from disease 
onset. 
The induction of oxazolone colitis depends on a variety of immunological processes and 
a better understanding of the role of IL-4 and IL-13 on individual cells would elucidate 
disease pathology. A recent paper in our lab (Horsnell et al. 2007) has shown the 
importance of IL-4/IL-13 responsive smooth muscle cells in the expulsion of the 
nematode Nippostrongylus brasiliensis. Mice deficient in the IL-4Rα specifically on 
smooth muscle cells (SM-MHCcreIL-4Rα-/lox) demonstrate delayed worm expulsion, 
delayed goblet cell hyperplasia and reduced Th2 cytokine production. From this data it 
was proposed that smooth muscle IL-4Rα is an important amplifier of Th2 cytokines 
from the mesenteric lymph node and surrounding tissue. If this reflects a general 
mechanism one might suggest that IL-4/IL-13 responsive smooth muscle cells also play 
a role in oxazolone colitis. Furthermore, alternatively activated macrophages (aaMph’s) 
have recently been shown to protect against colitis in a mouse model of Crohn’s disease 
(Hunter et al. 2009). The role of alternatively or classically activated macrophages has 
not been investigated in oxazolone colitis. Essentially, classically activated macrophages 
are induced by Th1 cytokines (IFN-γ) and are associated with tissue injury. In contrast, 
aaMph’s are activated by Th2 cytokines (IL-4 and IL-13) and are associated with the 















responses are responsible for the inflammation associated with UC, data obtained by 
using macrophage/neutrophil-specific IL-4Rα-deficient mice (LysMcreIL-4Rα-/lox) would 
be of interest in the oxazolone colitis model. On the one hand, an increase in classical 
macrophage activation leading to a shift towards increased Th1 responses could protect 
against Th2-induced colitis. On the other hand, aaMph’s are associated with tissue repair 
and preventing their activation could result in a more severe oxazolone-induced 
inflammation.  
In conclusion, several mouse models of IBD have been described, but few of these 
represent Th2-mediated colitis. By using the oxazolone-induced model of colitis we 
investigate the immune mechanisms involved in human UC. Genetically manipulated 
mice allow us to investigate the role of specific genes by loss of function. IL-4Rα-
deficient mice are a novel way to determine the function of IL-4 and IL-13 on individual 
cells in IBD and have not previously been described in the oxazolone model of UC. The 
results presented here clearly show the important role of IL-4Rα signalling in oxazolone 
colitis. In the past years substantial progress has been made in understanding the 
immunological mechanisms of IBD, resulting in exciting new therapeutic approaches. 
Given the heterogeneity of UC and the role of many cell types in disease onset, it is 
possible that blocking various signalling pathways could equally protect from the 
induction of colitis. Our data describe cellular mechanisms underlying mouse models of 
















3.1      References 
Boirivant, M., I. J. Fuss, A. Chu and W. Strober (1998). "Oxazolone colitis: A murine 
model of T helper cell type 2 colitis treatable with antibodies to interleukin 4." J 
Exp Med 188(10): 1929-39. 
Dewals, B., J. C. Hoving, M. Leeto, R. G. Marillier, U. Govender, A. J. Cutler, W. G. 
Horsnell and F. Brombacher (2009). "IL-4Ralpha responsiveness of non-CD4 T 
cells contributes to resistance in schistosoma mansoni infection in pan-T cell-
specific IL-4Ralpha-deficient mice." Am J Pathol 175(2): 706-16. 
Donaldson, D. D., M. J. Whitters, L. J. Fitz, T. Y. Neben, H. Finnerty, S. L. Henderson, 
R. M. O'Hara, Jr., D. R. Beier, K. J. Turner, C. R. Wood and M. Collins (1998). 
"The murine IL-13 receptor alpha 2: molecular cloning, characterization, and 
comparison with murine IL-13 receptor alpha 1." J Immunol 161(5): 2317-24. 
Girard, D., R. Paquin, P. H. Naccache and A. D. Beaulieu (1996). "Effects of interleukin-
13 on human neutrophil functions." J Leukoc Biol 59(3): 412-9. 
Gordon, S. (2003). "Alternative activation of macrophages." Nat Rev Immunol 3(1): 23-
35. 
Heller, F., I. J. Fuss, E. E. Nieuwenhuis, R. S. Blumberg and W. Strober (2002). 
"Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated 
by IL-13-producing NK-T cells." Immunity 17(5): 629-38. 
Herbert, D. R., C. Holscher, M. Mohrs, B. Arendse, A. Schwegmann, M. Radwanska, M. 
Leeto, R. Kirsch, P. Hall, H. Mossmann, B. Claussen, I. Forster and F. 
Brombacher (2004). "Alternative macrophage activation is essential for survival 
during schistosomiasis and downmodulates T helper 1 responses and 
immunopathology." Immunity 20(5): 623-35. 
Horsnell, W. G., A. J. Cutler, J. C. Hoving, H. Mearns, E. Myburgh, B. Arendse, F. D. 
Finkelman, G. K. Owens, D. Erle and F. Brombacher (2007). "Delayed goblet cell 
hyperplasia, acetylcholine receptor expression, and worm expulsion in SMC-
specific IL-4Ralpha-deficient mice." PLos pathog 3(1): e1. 
Hunter, M. M., A. Wang, K. S. Parhar, M. J. Johnston, N. van Rooijen, P. L. Beck and D. 
M. McKay (2009). "In vitro-derived alternatively activated macrophages reduce 
colonic inflammation in mice." Gastroenterology. 
Iijima, H., M. F. Neurath, T. Nagaishi, J. N. Glickman, E. E. Nieuwenhuis, A. Nakajima, 
D. Chen, I. J. Fuss, N. Utku, D. N. Lewicki, C. Becker, T. M. Gallagher, K. V. 
Holmes and R. S. Blumberg (2004). "Specific regulation of T helper cell 1-
mediated murine colitis by CEACAM1." J Exp Med 199(4): 471-82. 
Kojima, R., S. Kuroda, T. Ohkishi, K. Nakamaru and S. Hatakeyama (2004). "Oxazolone-
induced colitis in BALB/C mice: a new method to evaluate the efficacy of 
therapeutic agents for ulcerative colitis." J Pharmacol Sci 96(3): 307-13. 
Mohrs, M., C. Holscher and F. Brombacher (2000). "Interleukin-4 receptor alpha-
deficient BALB/c mice show an unimpaired T helper 2 polarization in response to 
Leishmania major infection." Infect Immun 68(4): 1773-80. 
Nelms, K., A. D. Keegan, J. Zamorano, J. J. Ryan and W. E. Paul (1999). "The IL-4 
receptor: signaling mechanisms and biologic functions." Annu Rev Immunol 17: 
701-38. 
Nieuwenhuis, E. E., M. F. Neurath, N. Corazza, H. Iijima, J. Trgovcich, S. Wirtz, J. 
Glickman, D. Bailey, M. Yoshida, P. R. Galle, M. Kronenberg, M. Birkenbach 
and R. S. Blumberg (2002). "Disruption of T helper 2-immune responses in 




















1.2 ml Anaket-V (100 mg/ml) (Centaur labs, Isando) 
0.8 ml Rompun (2 %) (Bayer, Germany) 
8.0 ml PBS (1X) 
Blocking Buffer 
20g  Milk powder (spar instant) (2 %) 
Make up to 1 L with 1X PBS 
Coating Buffer 
10 ml  10x PBS 
8g   BSA (Merck) 
Make to 1L in ddH2O and pH 9.5 
Dilution Buffer 
10g  BSA (1 %) (Roche) 
0.2g  NaN3 (0.02 %) (Merck) 
Make up to 1L with 1X PBS  
FACS Buffer 
0.1%  BSA (Roche) 
0.05% NaN3 (Merck) 
Made up in 1X PBS 
Iscove’s Modified Dulbeco’s Medium (IMDM) 
1 tube IMDM (Gibco) 
750 ml ddH2O 
81.7 ml NaHCO3 (37g / L) 
2 ml  Penicillin/streptomycin (500X) 
Adjust the pH to 7.2 – 7.4 
Make up to 1 L with ddH2O and filter sterilize 
Myeloperoxidase Assay 
0.5%  HTAB (hexadecyl trimethyl ammonium bromide) 
1mM  EDTA [HTAB buffer] 
1 tablet O-dianisidine in 8ml ddH2O 
0.005% H2O2 















Phosphate Buffered Saline (PBS 10X) 
80g  NaCl (1.37M) 
2g   KCl (0.03M) 
14.4g  H2PO4 (0.01 M) 
2.4g  KH2PO4 
Dissolve in 1 L ddH2O 
 
Red cell lysis buffer 
5 mM EDTA    150 mM  NaCl 
10 %  glycerol   25 mM  Tris-Cl pH 7.5 
0.1 %  SDS    1 %  Triton –X 100 
0.5 %  Non idet P-40   0.5 %  Deoxycholate 
5 mM PMSF 
Make to 1L with ddH2O 
Substrate Buffer 
0.2g  NaN3 (0.02 %) 
97 ml  di-ethanolamine 
0.8g  MgCl2.6H2O 
700 ml  ddH2O 
Adjust the pH to 9.8 and make up to 1 L with ddH2O 
Washing buffer 
20g  KCL    20g  KH2PO4 
144g  NA2HPO4.H2O  800g  NaCl (Merck-BDH) 
50 ml  Tween 20 (Sigma)  100 ml  10 % NaN3 (Merck)  


















Disease activity index scoring sheet: 
Appearance  Natural Behaviour  
Normal 0 Normal 0 
General lack of grooming 1 Minor changes 1 
Coat staring. Ocular and nasal discharges 2 Less mobile and alert, isolated 2 
Piloerection, hunched up 3 Vocalization, restlessness, very still 3 
Clinical signs  Provoked behaviour  
Normal colour & movement 0 Normal 0 
Slight changes in activity 1 Minor depression or exaggerated response 1 
Moderated Changes: weight loss, diarrhoea 2 Moderate change in exoected behaviour 2 
Severe changes: immobility, lameness 3 Reacts violently or very weak 3 
* If 3 was scored more than once, an extra point was scored for every 3. Total = 16 
Lung tissue single cell suspensions 
Individual lungs were cut into small pieces using a scalpel blade and incubated in 
DMEM (Gibco) containing 50U/ml Collagenase I (Gibco-INvitrogen) and 13μg/ml 
DNAse I (Roche, Germany) for 90 min at 37°C. The tissue was pressed through a 70 
μm sieve and red blood cells (RBC) were lysed with lysis buffer for 5 min on ice. The 
remaining cells were collected by centrifugation (1200 rpm for 5 min at 4°C) and 
stained with CD23, CD19 or CD3 mAbs for FACS analysis. 
Bicinchoninic Acid Protein Estimation (BCA) 
The BCA protein assay (Pierce, Rockford, USA) was used to determine the protein 
concentration of all samples. The principle of this method is the reduction of Cu2+ to 
Cu1+ by protein in an alkaline medium with the colorimetric detection of the cuprous 
cation (Cu1+) by bicinchoninic acid. The rate of BCA colour formation (purple) is 
dependent on the incubation temperature, the types of protein present in the sample and 
the amounts of reactive amino acids in the proteins. The protein standard was prepared 
by diluting Bovine Serum Albumin (BSA) in the same diluent as the samples (diluted 
10 fold down). The BCA working solution was added and after incubation at 37 ºC for 
30 min the absorbance was measured at 540 nm using a microplate spectrophotometer 
















Preparation of histology sections 
Tissues were dehydrated in an automated processor and embedded in wax as indicated 
below: 
70% alcohol   30min 
96% alcohol (2x)  45min 
100% alcohol (4x)  45min 
Xylol (2x)   60min 
Wax (55°C-60°C) (2x)  45min (with vacuum) 
The tissues were sectioned at 2μm with a microtome, floated onto glass slides and fixed 
by incubation at 37°C overnight. The wax was removed from sections by incubation at 
60°C for 2-18h and then rehydrated as follows: 
Xylol    30min 
Xylol (2x)   1 min 
100% alcohol  1min 
96% alcohol   1min 
70% alcohol   1min 
Water   1min 
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